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ABSTRACT 
Nutraceuticals (i.e., food-derived bioactive compounds) are a vast and relatively untapped 
resource for novel anti-cancer drug discovery. Our lab created a unique nutraceutical library and 
screened these compounds in two human acute myeloid leukemia (AML) cell lines (KG1a and 
OCI-AML2) and one “normal” prostate cell line (RWPE) for selective anti-cancer activity.  
Glucopsychosine, a lipid derived from bovine milk, reduced the viability of leukemia cells 
without altering viability of normal cells at concentrations up to 10 µM, as measured by the MTS 
assay. To confirm its activity, glucopsychosine demonstrated a dose response against AML cell 
lines (n=3) with an EC50 of 3.5-5.0 µM with no effect on the viability of normal bone marrow 
derived CD34+ cells at concentrations up to 20 µM, as measured by the Annexin V/Propidium 
iodide (ANN/PI) assay. Time course analysis showed that glucopsychosine induced apoptosis 
following 12 hours of incubation, as evidenced by accumulation of ANN+/PI- cells. Apoptosis 
was further confirmed, using standard apoptotic assays, as glucopsychosine caused DNA 
fragmentation, caspase activation and PARP cleavage.  
Given the observed in vitro effects, we next evaluated glucopsychosine’s in vivo anti-
tumor efficacy in leukemia mouse xenografts. NOD/SCID mice (n=24) were subcutaneously 
injected with OCI-AML2 leukemia cells and then given glucopsychosine (20 mg/kg or 40 
mg/kg) or a vehicle control every other day for 17 days by intraperitoneal injection.  
Glucopsychosine delayed tumor growth and reduced tumor weight up to 4 fold (p<0.05) 
compared to control without evidence of weight loss or changes in red blood cell counts, 
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hemoglobin levels or serum markers of kidney and liver damage. Therefore, glucopsychosine 
imparted anti-tumor activity without toxicity.  
Glucopsychosine caused a significant 2-3 fold increase (p<0.001) in cytosolic calcium 
levels at 4-8 hours of incubation, as measured by the fluorescent intracellular dye fluo-3AM and 
flow cytometry. Since increases in cytosolic calcium can initiate apoptosis through calpain 
activation, we measured the activity of these calcium dependent proteases using a commercially 
available activity assay and by Western blotting. Following 6-8 hours of incubation, 
glucopsychosine resulted in a 3 fold increase in calpain activity (p<0.01) and active calpain 
protein levels. Moreover, co-incubation with the calpain inhibitor MDL28170 significantly 
abrogated calpain activation (p<0.01) and AML cell death (p<0.05).   
To assess the source of calcium, we measured glucopsychosine’s ability to increase 
cytosolic calcium and induce death following co-incubation of AML cells with verapamil, 
cyclosporine A or TMB-8, which block increases in cytosolic calcium mediated by surface 
channels, mitochondria or endoplasmic reticulum, respectively.  Only verapamil abrogated 
glucopsychosine induced increases in cytosolic calcium and toxicity suggesting that the source of 
calcium in glucopsychosine mediated AML cell death is from the extracellular space. This 
hypothesis was confirmed as we demonstrated that glucopsychosine-induced apoptosis was 
absent when AML cells were cultured in calcium free media. Finally, we interrogated publicly 
available AML gene expression profiling datasets for changes in expression of surface calcium 
channel subunits in AML patient samples compared to normal hematopoietic cells. Multiple 
subunits of CACNA1, a voltage dependent plasma membrane calcium channel, are significantly 
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(p<0.001) under-expressed >1.5-fold in AML patients compared to normals. Given recent 
evidence that AML cells possess low intracellular calcium levels and elevated calpain activity, 
our data suggests that glucopsychosine’s mechanism of AML selectivity may be directly related 
to its ability to target and activate this apoptotic pathway.  
Thus, glucopsychosine increases cytosolic calcium to induce calpain mediated apoptosis 
and displays pre-clinical activity in leukemia mouse xenografts. Glucopsychosine is a lipid 
derived from bovine milk and given its observed safety profile it could be useful in the treatment 
of acute myeloid leukemia.  
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CHAPTER 1:  LITERATURE REVIEW 
1.1  Acute myeloid leukemia 
Leukemia, a malignancy of the blood, will affect 52,380 new American patients in 2014. 
Thirty percent of those patients will be further classified as having acute myeloid leukemia 
(AML).  According to the American Cancer Society, the estimated number of deaths in the 
United States attributable to AML will be 10,460 people [1].  This implies that in 2014, 28 
people per day will die from AML in the United States alone.  Even though the median age is 67 
[2] at the time of diagnosis, AML is also prevalent in children.  Leukemia is the most common 
pediatric cancer (34 percent of new cancer cases in children is leukemia, either ALL or AML) 
[3].  Since AML is a heterogeneous disease, five-year survival rates in children range from 90 
percent (in the most favourable prognostic group) to as low as 22 percent [4].  Unfortunately, 
these statistics only decrease as age increases - older AML patients (>60 years old) having a 
reported five-year survival rate of less than 10 percent [5].  AML is a devastating disease that 
indiscriminately occurs in all ages and people groups. 
Leukemia is the cancer of haematological processes.  Haematopoiesis is the process by 
which all blood cell-types are formed, starting with a haematopoietic stem cell found in the bone 
marrow that is capable of differentiating or self-renewing itself.  It is able to differentiate into 
myeloid progenitor cells or lymphoid progenitor cells.  In AML, differentiation is arrested at the 
myeloid progenitor level which leads to the accumulation of immature myeloid cells referred to 
as “myeloid blasts” [6].   
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The objectives of AML treatment is to induce complete remission (CR) and prevent 
patient relapse.  CR, defined by the National Cancer Institute, is the achievement of specific 
hematologic parameters (no extramedullary leukemia, neutrophil recovery, and platelet recovery) 
and less than 5 percent bone marrow myeloid blasts [7].  Cytarabine and daunorubicin have been 
the standard chemotherapeutics used for the treatment of AML since their discovery in the 
1960’s [8, 9].  Slight dosing modifications have improved treatment efficacy of these drugs.  
However, a large portion of AML patients cannot tolerate these chemotherapeutics, due to their 
dose limiting toxicities.   
1.1.1 Pathology 
The etiology of AML begins with DNA mutation (i.e., cytogenetic lesions) which 
includes deletions and translocations in certain chromosomes.  The most prevalent genetic 
deletion in AML is the t(15;17) translocation which is present in over 90 percent of AML cases 
[6].  AML can be classified under the French-American-British (FAB) system which divides 
AML into 8 different groups (M0-M7) via their cytogenetic properties.  Recently, the FAB 
system of classification was updated by the World Health Organization’s (WHO) classification 
system which integrates genetic, immunophenotypic, biological, and clinical features of AML 
[10].  Irrespective of the classification system used, classifying AML on common disease state 
phenotype can aide in selecting appropriate treatment.  The primary example of this is the 
t(15;17) deletion which has been sub-classified as acute promyelocytic leukemia (APL).   
The translocation seen in APL results in the formation of a PML/RARα fusion protein 
which arrests myeloid cell differentiation by incorrectly localizing PML within the cell [11].  It 
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was discovered that all-trans retinoic acid restored cell differentiation by enabling the proper 
distribution of PML.  Now APL is treated with the highest success rate of all AML prognostic 
groups with expected cure rates of greater than 70 percent [12].   This provides evidence that 
novel therapies can be developed and catered to specific AML sub-types.  However, AML is a 
heterogeneous disease which in most cases is the result of multiple mutations.   
1.1.2 Diagnosis 
In AML, the normal myeloid cells in the body are replaced with leukemic blasts that 
deplete the body of their normal blood proportions which results in cytopenia (a reduction in the 
number of blood cells).  Fatigue, hemorrhaging, and an increased predisposition to infections and 
fevers are common in AML patients because of decreases in red blood cells, platelets, and white 
cells respectively [6].  When AML progresses, the leukemic cells in the bone marrow can escape 
into the blood system and can cause granulocytic sarcomas (isolated leukemic tumors) and 
hyperleukocytosis (>100,000 white blood cells per mm3).   
 As a general rule, AML is diagnosed in a patient when their myeloid blasts in bone 
marrow or blood exceeds 20 percent (according to the WHO criterion) [2].  The number of 
myeloid leukemia cells can be measured via multicolor flow cytometry by counting cells 
expressing cell markers unique to myeloid cells such as CD33, CD13, CD64, or CD41.  
Although there are different prognostic groups, patients with myelodysplastic syndromes (MDS; 
11-19 percent white blood cells in bone marrow or blood) [6] may fare better with AML 
treatment options and AML patients with >20 percent blasts may fare better with MDS treatment 
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options.  Therefore, multiple parameters such as cytogenetics or immunophenotype must also be 
considered before making any clinical decisions [2].     
1.1.3 Treatment 
Patients are diagnosed based on cytogenetics, age, karyotype and clinical features of 
AML (white blood cell count, platelets, and bone marrow blasts) [10]. This ranges from 
favourable to unfavourable, depending on which classification system one uses (refer to Ch. 
1.1.1).   
The gold standard of AML treatment has been the combination of cytarabine (AraC, a 
pyrimidine analogue) with an anthracycline such as daunorubicin.  Daunorubicin and AraC (DA) 
was introduced in 1960’s and it was the first instance of inducing CR in an AML patient [8].  
Daunorubicin is administered at 45-60 mg/m2/d for 3 days and is combined with standard-dose 
cytarabine at 100-200 mg/m2 over 7 days. This is known as the “3+7 induction regimen” and it 
induces CR in 65 to 75 percent of younger patients (<60 years of age) and 50 percent in older 
patients (>60 years of age) [9, 13].  While these numbers are promising, the rate of relapse in the 
favourable subgroup of AML patients is 30 to 40 percent (and they increase depending on their 
prognostic group) [6].  The disease free survival of this treatment is 30 percent of patients for 
long-term (>5-years).  Cytarabine is also used at higher doses in the next stages of therapy – 
consolidation, maintenance, and salvage therapy – which focuses on keeping remission and 
ridding the body of any residual cancer. 
Dosing modifications and adding other chemotherapeutics, such as etoposide, have been 
tested over the years yielding important facts about AML treatment.  Studies assessing high-dose 
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cytarabine treatment (2-3 g/m2) show a lack of evidence for better CR rates with an increased 
intensity of induction therapy.  The same is true when studies were done with a second phase of 
induction therapy [13].  Clinicians try to increase CR of their patients by making dosing 
modifications, rotating new chemotherapeutics with the 3+7 regimen, or adding additional 
rounds of induction chemotherapy.  Ultimately, novel therapies are needed to improve disease 
outcomes for these patients.   
1.2 Nutraceuticals 
 The term “nutraceutical” was coined in 1989 by Dr. Stephen DeFelice and the Foundation 
for Innovation in Medicine as,  
“…any substance that may be considered a food or part of a food and that provides 
medical or health benefits, including the prevention and treatment of disease.  Such 
products may range from isolated nutrients, dietary supplements and diet plans to 
genetically engineered 'designer' foods, herbal products and processed foods such 
as cereals, soups and beverages.” [14] 
Nutraceuticals are a component of a larger family of compounds known as natural health 
products (NHPs) which accounts for a third of Consumer Health Products Canada member’s total 
sales indicating their prevalence in health care in Canada [15].  As of late, many research 
initiatives are looking to nutraceuticals as potential cures to a wide array of diseases.  This is not 
a new phenomenon, but one of the oldest forms of drug discovery.  The bioactive components of 
foods have been known to affect many biological processes related to neoplastic growth such as 
cell differentiation, apoptosis, cell cycle, carcinogen metabolism, inflammatory responses, and 
DNA repair [16]. 
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From 1981-2002, NHPs represented 28 percent of the number of new drugs introduced in 
addition to the 24 percent of new chemical compounds derived from a natural product 
pharmacophore [17].  From 2005 to 2007 there were thirteen NHP-derived drugs that were 
approved and currently there are over a hundred NHP-derived drugs undergoing clinical trials 
[18].  Because natural products are chemically diverse, previously identified therapeutic NHPs 
can and should be reassessed for potential efficacy in other diseases.  Of the 25,000 nutraceutical 
compounds, only 500 of these compounds have been assessed in studies for cancer treatment and 
prevention [16].  Drug repurposing libraries have increased in popularity because of emerging 
technologies and new methods of high-throughput screening.  Therefore, nutraceuticals are a 
valuable source for drug discovery or repurposing as they are an underrepresented subcategory of 
NHPs. 
1.2.1 Glucopsychosine 
Glucopsychosine, also known as glucosylsphingosine, is naturally found in milk as a 
membrane lipid [19].  It is a modified glycosphingolipid which are ubiquitous in all eukaryotic 
membranes.  Glucopsychosine is composed of a glucose sugar attached to a sphingosine at the 
C1 hydroxyl group (Figure 1) [20].  In the body, glucopsychosine is broken down and 
metabolised by the enzyme glucosylceramide-β-glucosidase (GβGase) into psychosine [20, 21].  
It has been reported that psychosine accumulation in the central nervous system, as seen in 
Gaucher disease patients, is due to a decreased amount of GβGase activity.  An experiment by 
Jatana et al. (2002) [21] showed that the IC50 in rat C6 glial cells after 24 hours was 20 µM.  
Lloyd-Evans et al. (2003) [22] showed that glucopsychosine may be involved in sensitizing 
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ryanodine receptors on the endoplasmic reticulum (ER) membrane to allow the efflux of Ca2+ 
ions into the cytosol in brain microsomes.  There has been no research to date assessing 
glucopsychosine’s toxicity in AML cells.   
 
Figure 1. Glucosylsphingosine (glucopsychosine) chemical structure.  
 Membrane lipids can participate in many complex cell-to-cell signalling events due to the 
wide diversity of their headgroups and formations.  The ceramide/sphingomyelin pathway 
utilizes lipids as second messengers for regulating apoptosis [23].  The precursor lipids are 
sphingolipids which are generated in the ER.  Sphingolipids are classified by their characteristic 
eighteen carbon amino-alcohol backbone which can be used as a precursor to all other 
sphingolipid modifications [24].  Sphingosine (Fig. 1) can be modified to become a pro-apoptotic 
or an anti-apoptotic second messenger.  Phosphorylation of the C1 hydroxyl group leads to the 
anti-apoptotic lipid signaller sphingosine-1-phosphate while acylation of sphingosine produces 
ceramide molecules which are generally pro-apoptotic [25]. 
1.3 Programmed cell death 
There are three main cell death pathways.  These are apoptosis, autophagy, and necrosis.  
Autophagy differs from apoptosis and necrosis because it primarily functions as a pro-survival 
mechanism during cellular stress by recycling cellular components through the merging of 
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autophagic vesicles (containing damaged parts) and lysosomes.  However, in the presence of 
prolonged autophagic signalling the cell may use autophagy as a mode of cell death [26, 27].  
Necrosis was once thought of as an unregulated form of cell death, but recent studies suggest that 
necrosis can be genetically regulated [27].  Apoptosis is a genetically regulated process of cell 
death where cells systematically undergo a series of morphological changes and are consumed by 
surrounding cells.  The term “programmed cell death” refers to any genetically controlled form 
of cellular termination [26].   
1.3.1 Apoptosis 
More than 50 percent of neoplasms have dysfunctional apoptotic machinery [26].  While 
uncontrollable apoptosis can lead to degenerative diseases, insufficient apoptosis will lead to 
uncontrollable proliferation.  The tumor suppressor gene TP53 is an oft mutated gene in 
neoplastic diseases and results in the inactivation of p53.  p53 is a sensor of genotoxic stress 
during DNA damage acts as an apoptotic switch.  In the absence of this sensor, but in the 
presence of DNA damage, cells will continue to function as normal because there is no input 
from p53 [26].  This will ultimately lead to unregulated cell division of damaged DNA.   
Apoptosis can be induced by DNA damage, nutrient starvation, reactive oxygen species 
production, death-receptor ligand binding, calcium increases, and other cellular stresses.  The 
characteristics of apoptosis are cell shrinkage, chromatin condensation, membrane blebbing, the 
formation of apoptotic bodies, and the lysis and phagocytosis of apoptotic bodies by surrounding 
cells [28].  An early marker of apoptosis is the flipping of phosphatidylserine (PS) to the outer 
leaflet of the plasma membrane.  This process is mediated by two enzymes – Ca2+-dependent 
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scramblases and ATP-dependent aminophospholipid translocases [29].  Phagocytes recognize PS 
and target the apoptotic cells for degradation [28]. 
Caspases are cysteine aspartic proteases which are functionally inactive until cleaved at a 
specific site.  They play key roles in cytoskeletal degradation and nuclear fragmentation.  There 
are fourteen known caspases, but not all are involved at the same time [28].  Depending on the 
pathway of apoptosis, different caspases can be activated.  Caspase-3 and -7 are known as the 
executioner caspases because they are involved in the final proteolytic event in many apoptotic 
pathways.  Caspase-3 and -7 can cleave the DNA repair protein, poly(ADP-ribose)ylation 
polymerase (PARP) [30, 31] at the DEVD (Asp-Glu-Val-Asp) tetrapeptide site rendering PARP 
unable to repair DNA.  The inactivation of PARP allows DNA fragmentation, which is 
characteristic of all apoptotic pathways.   
1.3.2 Pathways of apoptosis 
The death receptor pathway is initiated via external factors that cause the cell to undergo 
apoptosis directly.  Death receptors situated on the outer leaflet of the plasma membrane 
commence the apoptotic response when bound by pro-apoptotic ligands.  The six known death 
receptors are CD95, DR2, DR3, DR4, DR5, and TNR1 [32]. The death-inducing signalling 
complex (DISC) is assembled upon a ligand (from the TNF-superfamily) binding to the death 
receptor. The FAS-associated death domain (FADD) adaptor protein then recruits caspase-8, 
which can induce apoptosis through proteolytic cleaving of procaspase-3 thereby activating it. In 
addition, there can be crosstalk between the death receptor pathway and the intrinsic pathway 
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through caspase-8’s ability to cleave Bid (Fig. 2).  Truncated-Bid (tBid) is an inhibitor of anti-
apoptotic proteins found in the mitochondria [26, 32].    
 
Figure 2. Death receptor and intrinsic mitochondrial pathway of apoptosis. Modified from 
Hotchkiss et al. Cell death. N Engl J Med. 2009 [33].  The death receptor pathway involves the 
binding of a death ligand to a death receptor (CD95, DR2, DR3, DR4, DR5, and TNR1) located 
on the cell membrane.  This complex recruits caspase-8 which can then activate caspase-3 or cleave 
Bid (cross-talk with the intrinsic pathway).  The intrinsic pathway is initiated by various cellular 
stresses which causes a loss in mitochondrial membrane integrity which allows cytochrome c 
(found in the inner mitochondrial membrane) to be released activating the caspase-9 cascade.  
Caspase-3 activation leads to the cleavage of PARP (a DNA repair protein) and the execution of 
apoptosis.  
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The intrinsic pathway is mediated by many mitochondrial related proteins which are 
either anti-apoptotic or pro-apoptotic.  Anti-apoptotic proteins such as Bcl-2 and Bcl-xL are in 
constant flux with pro-apoptotic proteins including (but not limited to) Bid, Bak, Bax, and Puma. 
Ultimately, the intrinsic pathway of apoptosis leads to the loss of mitochondrial membrane 
potential (∆Ψm) and the release of apoptotic effector proteins from the inner mitochondrial 
membrane matrix [26, 34].  Cytochrome c is one of these inner mitochondrial membrane matrix 
proteins and, when released, is a part of the apoptosome complex.  This complex allows the 
activation of procaspase-9 which then results in the proteolytic activation of the executioner 
caspases and leads to apoptosis [34].  Therefore, regulation of cytochrome c release is Bcl-2 and 
Bcl-xL’s role.  The cleavage of Bid to tBid causes the inhibition of Bcl-2/Bcl-xL and the 
activation of Bax and Bak [26]. 
Less common pathways of apoptosis involve the ER, calcium, and the calpain family of 
cysteine proteases.  The ER is the organelle that folds and post-translationally modifies peptides 
for further packaging and compartmentalization.  When there is an accumulation of unfolded 
proteins, the unfolded protein response (UPR) occurs in hopes to salvage cells.  The UPR causes 
an up-regulation of GRP78 protein chaperone which shuttles unfolded proteins back into the ER 
lumen to stimulate protein folding and circumvent apoptosis [35].  However, in the state of 
prolonged UPR, the cell may undergo apoptosis via the ER stress pathway. 
The ER stress pathway involves procaspase-12 which, in its inactive state, is bound to the 
cytosolic side of the ER.  Procaspase-12 is activated by m-calpains in the cytosol and can go on 
to initiate the caspase cascade via caspase-3 and -7 activation.  Apart from cleaving PARP, 
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caspase-3 also cleaves calpastatin – an endogenous inhibitor of calpains in the cytosol – leading 
to a positive feedback loop with caspase-3 and calpains [36].  Caspase-12 is also able to activate 
caspase-9 which is involved in the intrinsic mitochondrial pathway and this presents a 
cytochrome c independent model of apoptosis [35].   
 
 
Figure 3.  ER stress mediated apoptosis and the various sources of calcium influx.   ER stress 
can be initiated by a depletion of ER calcium stores or large and rapid influx of extracellular 
calcium into the cytosol.  When GRP78 is inefficient in shuttling unfolded proteins back to the ER, 
pro-caspase-12 translocates from the ER membrane to be activated by active calpain.  Under 
normal conditions calpains are inhibited by calpastatin, but calcium binding releases calpastatin 
from calpains enabling them to cleave procaspase-12.  The caspase-12 cascade can cause apoptosis 
by activating caspase-3 and 7 directly or    through caspase-9.  
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The ER stress pathway can also act independently of caspase-12 by causing the loss of 
∆Ψm and the release of cytochrome c or endonuclease G [37].  Endonuclease G is a DNase that 
can fragment DNA [34, 37].  While there has been little focus on the ER stress pathway, new 
studies are showing that it is involved in many cell death related programs.  Research into 
curcumin and its anti-cancer effects in HL60 cells shows that curcumin causes apoptosis via the 
ER stress pathway [38]. 
1.3.3 The calpain cysteine proteases 
The calpains are a family of Ca2+-activated cysteine proteases that are located exclusively 
intracellularly in all mammalian cells.  There are two classes of calpains which are ubiquitously 
expressed – µ-calpain and m-calpain. These calpains require different concentrations of calcium 
in order to become active. µ-Calpains require micromolar concentrations (3-50µM) whereas m-
calpains need millimolar (400-800 µM) concentrations of calcium [39].  Structurally, these 
proteins are highly conserved and similar, with µ-calpain being slightly larger than m-calpain.  
Calpains are heterodimeric proteins consisting of a large domain (~80 kDa) and a small domain 
(~28 kDa) [40].  The large subunit is composed of four domains (I, II, III, and IV) and domain I 
is autolysed prior to activating its proteolytic function.  The small subunit is composed of two 
domains (V and VI) and contains a lethality gene which highlights the importance of these 
proteases for regulating key processes [41].  These proteases reside predominantly in the 
cytoplasm, however, multiple studies have confirmed that they are redistributed to subcellular 
locations during mitosis/meiosis, as they play essential roles in cell cycle progression [41].   
  14 
Calpains are constitutively inhibited by calpastatin to prevent unspecific activation by 
normal Ca2+ flux [36].  These inhibitors are heat stable and calpain-specific, resistant to many 
denaturing agents such as urea, SDS, or trichloroacetic acid. One calpastatin molecule (110 kDa) 
can inhibit four calpain molecules because of its four repeating domains [39].  Calpastatin also 
requires calcium to inhibit calpains, however, the amount of calcium needed is significantly 
lower and therefore has a prevailing tendency to keep calpains inhibited.  Calcium does not bind 
to calpastatin, but instead to calpains at a specific site which allows calpastatin to block the 
autolysis of calpain [39, 40].  In the presence of excess Ca2+ levels, calpastatin will dissociate and 
allow calpains to autolyse and become an active protease against various substrates including its 
own inhibitor, calpastatin [39]. 
Once activated, calpains can act on a variety of substrates located in the cytosol, nucleus 
(including PARP), or plasma membrane [39].  Calpains can initiate apoptosis independent of 
caspase enzymes.  This involves release of mitochondrial proteins such as apoptosis inducing 
factor (AIF) and endonuclease G.  AIF becomes truncated by calpains and translocated from the 
mitochondria to the cytosol and then to the nucleus where it initiates chromatin condensation and 
DNA fragmentation independent of caspases [42].  However, there is still crosstalk between 
calpains and caspases [36].  Caspase-3 can cleave calpastatin to free calpains from their inhibitor. 
Many studies have shown calpains involvement in cell cycle progression [40, 41, 43].  
Calpains are essential proteases during S phase and G2/M phase cell cycle checkpoints.  
Inhibiting calpains causes arrest at multiple points on the cell cycle.  In cells arrested at the G1/S 
phase, addition of GM-CSF (a mitogen) resumed cell cycle progression after 9 hrs in TF-1 cells, 
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but it took 18 hours in the presence of a calpain inhibitor, PD 150606 [41].  It is hypothesized 
that calpains regulate cell cycle by degrading p53, a tumor suppressor protein, which leads to the 
down-regulation of the Cdk inhibitor, p21 [41]. This has implications in regards to cancer cell 
morphology because calpains therefore promote oncogenesis within cells.  Niapour et al. [44] has 
shown that AML cells have elevated levels of calpains which could be used by the malignant 
cells to accelerate cell division in AML.  
1.4 Calcium 
  Cellular signalling is mediated through the binding of one compound which causes a 
chemical or structural change to another compound or protein.  Protein kinases, for example, 
remove the γ phosphate (high energy) from an ATP molecule and attach it to the hydroxyl group 
of a substrate protein residue (e.g., serine, tyrosine, or threonine) which further changes the 
properties of that protein [45].  Calcium is a very potent cell signalling molecule due to its 
distinguishing characteristics.  As an alkaline earth metal it carries a +2 charge when ionised.  
This enables it to bind a large array of proteins causing conformational and polarity changes  
which can elicit a signal [46].  The normal physiological range of cytosolic Ca2+ is 100 nM which 
is significantly less than the extracellular Ca2+ concentration of 2 mM [36, 46].  This 20,000-fold 
gradient allows for large and rapid cellular signalling.  Additionally, cells can finely regulate 
cytosolic Ca2+ for signalling events that require only transient rises in cytosolic Ca2+.  
1.4.1 Calcium channels 
Increases in cytosolic Ca2+ can occur either by release from intracellular stores or influx 
from the extracellular space through plasma membrane channels.  The main calcium stores are 
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mitochondria, the ER, and the sarcoplasmic reticulum (SR) which can be controlled by various 
second messengers.  Calcium itself can act as a second messenger to release more calcium into 
the cytosol from intracellular stores [47].  Calcium signalling can be split into “on” and “off” 
reactions.  “On” reactions include second-messenger signalling that promote the influx of free 
calcium into the cytosol.  In contrast, “off” reactions refer to the removal of free Ca2+ mediated 
by intracellular buffers, pumps, and exchangers [47].  The homeostasis of calcium is dependent 
on the balance of these reactions.  Cellular processes controlled by calcium signalling will differ 
based on the spatial and temporal increases in calcium.  For example, sustained and high levels 
of cytosolic Ca2+ will result in cellular events such as gene transcription and proliferation [48], 
while transient fluctuations can trigger exocytosis [49].  For apoptosis to be triggered by calcium, 
sustained increases in calcium or depletion of intracellular stores beyond a threshold is required.  
Channels and pumps which span the plasma membrane are the main regulators of cytosolic Ca2+.   
Calcium ions are not readily diffused across the plasma membrane, but slight increases in 
membrane permeability could result in large influx because of the calcium-gradient.  If the 
membrane is not compromised, calcium can enter the cell through multiple integral proteins.  
The types of calcium channels found on the cell surface are voltage-gated, ligand-gated, store-
operated channels, and sodium-calcium exchangers [46, 48].  Voltage gated channels open when 
the membrane is depolarized below a threshold [50].  When intracellular stores are depleted, 
store-operated channels on the plasma membrane can open to allow calcium to “refill” the stores 
[48].  Ligand gated channels can be further divided into receptor operated channels, which are 
activated by binding of an agonist to an allosteric site, or second-messenger operated channels 
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which are activated by a variety of molecules such as inositol phosphates and lipid-derived 
molecules [48].  Lastly, calcium can enter through sodium-calcium exchangers in certain cases as 
it is usually used to pump calcium out of the intracellular space [46].  Cells are very sensitive to 
cytosolic Ca2+ and have multiple intra and extracellular pumps to reduce cytosolic Ca2+ levels.  
ATPase pumps are sanctioned to continually push Ca2+ ions into the ER or SR via 
sarcoendoplasmic reticular Ca2+ ATPase (SERCA) pumps or out of the cell through plasma 
membrane Ca2+ ATPase (PMCA) pumps [46].  Therefore, the cell is able to control and monitor 
its cellular Ca2+ levels through various channels giving it control of its intracellular Ca2+ levels.   
1.4.2 Calcium and apoptosis 
Calcium plays a key role in early apoptosis.  Recall that calcium is involved in the 
flipping of phospholipids to the outer leaflet of the plasma membrane.  An early event in 
apoptosis is the externalization of PS which signals for phagocytic degradation.  While the exact 
mechanism of Ca2+ in this process is unclear, it is understood that the flipping of PS is Ca2+ 
dependant but not Ca2+ regulated [36].  It was thought that intracellular Ca2+ levels needed to be 
in the 25 to 100 µM range, but a recent paper by Weiss et al. showed Ca2+-dependent scramblase 
achievable at an EC50 of as low as 1.2 µM [29].   
As mentioned previously, calpains are Ca2+-activated cysteine proteases and can lead to 
apoptosis through multiple apoptotic pathways.  Few chemotherapeutics focus on calcium 
regulation as a mechanism for cancer treatment.  Suramin, paclitaxel, and vincristine are of the 
few chemotherapies reported to illicit a calcium response within the cell.  Of the three mentioned, 
only vincristine has benefits in AML treatment specifically [51].  
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CHAPTER 2:  OBJECTIVES AND HYPOTHESIS 
The objectives of this project are: 
1. Characterize glucopsychosine’s mechanism of action in acute myeloid leukemia cells in 
vitro and;   
2. Determine glucopsychosine’s efficacy ex vivo and in vivo using primary patient samples 
and animal models, respectively.  
These objectives fulfilled the original hypothesis that: 
Glucopsychosine is selectively cytotoxic to myeloid leukemia cells and increases the 
levels of intracellular calcium which ultimately leads to apoptosis. 
 
Short term goals: 
Complete the preclinical research and relevant literature review necessary for 
glucopsychosine to warrant further investigation into clinical use for acute myeloid leukemia.  
This will be accomplished by performing experiments to understand glucopsychosine’s 
mechanism of action and demonstrate its in vivo efficacy and safety. 
 
Long term goals: 
Upon successful completion of the aforementioned short term goals, the next steps would 
be to 1) understand the pharmacokinetic properties of glucopsychosine in humans, 2) begin 
Phase 1 clinical trials. 
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3.1 Introduction 
Acute myeloid leukemia (AML) is an aggressive malignant disease characterized by the 
clonal expansion of myeloid precursors that fail to terminally differentiate (i.e., blasts) [6]. Front-
line AML therapy consists of 3 days of daunorubucin (45–90 mg/m2) and 7 days of continuous 
intravenous infusions of cytarabine (100 mg/m2) and results in complete response rates up to 
80% [52]. However, within 2 years there may be a reoccurrence of disease that is resistant to 
induction chemotherapy [53]. Although recent advances have improved therapies for other 
hematological malignancies, AML therapy has remained essentially unchanged for 30 years [54]. 
Thus, there is a critical need for new, more efficacious AML therapies. 
Nutraceuticals are food-derived bioactive compounds with physiological activity and 
belong to a larger group of molecules known as natural health products. While the role of 
nutraceuticals in cancer treatments is largely unknown, recent studies have demonstrated that the 
natural health products kinetin riboside [55], an adenosine derivative from coconut milk, and 
parthenolide [56], an extract from the medicinal herb feverfew, possess anti-leukemia activity. 
Given these findings, we hypothesized that nutraceuticals would possess similar anti-leukemia 
activity. Since nutraceuticals are under-represented in large commercially available libraries, we 
compiled a unique nutraceutical-specific library consisting of 30 compounds and screened this 
library against AML cell lines to identify novel anti-leukemia nutraceuticals. From this screen, 
we identified glucopsychosine (GLU), a lipid derived from bovine milk. 
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3.2 Materials and methods 
3.2.1 Reagents 
Glucopsychosine was obtained from Matreya, Inc. (Pleasant Gap, PA) and reconstituted 
in 100% ethanol. The stock solution (5 mM) was diluted in phosphate buffered saline (PBS), 
aliquoted and stored at −20 °C to prevent excessive freeze thaw cycles. Fluo-3AM (Life 
Technologies; Grand Island, NY), z-VAD-FMK (Z-VAD; R&D Systems, Minneapolis, MN), 
Verapamil, Q-VD-OPh, 8-(N,N-Diethylamino)-octyl-3,4,5-trimethoxybenzoate HCl (TMB-8) 
and cyclosporin (Sigma Chemical; St. Louis, MO) and MDL28170 (Tocris; Bristol, UK) were 
purchased and reconstituted according to manufacturer’s protocols. 
3.2.2 Cell culture 
Acute myeloid leukemia (OCI-AML2, KG1A, U937) cell lines were cultured in Iscove’s 
Modified Dulbecco’s Medium (IMDM; Life Technologies; Grand Island, NY) supplemented 
with 10% fetal calf serum (FCS; Hyclone, Logan, UT) and antibiotics (100 units/mL of 
streptomycin and 100 µg/mL of penicillin; Sigma Chemical). RWPE-1, normal prostate cells 
were incubated in keratinocyte serum free media (Life Technologies). Cells were incubated in a 
humidified air atmosphere containing 5% CO2 at 37 °C. 
Primary human AML samples, obtained from Dr. Mark Minden, Princess Margaret 
Cancer Center, were cultured at 37 °C in IMDM, 20% FCS and antibiotics. These cells were 
isolated from the peripheral blood of consenting AML patients who had at least 80% malignant 
cells among the mononuclear cells. Normal bone marrow-derived CD34+ hematopoietic cells 
were purchased from Stem Cell Technologies (Vancouver, BC). The collection and use of human 
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tissue for this study was approved by institutional ethics review boards (University Health 
Network, Toronto, ON, Canada and University of Waterloo, Waterloo, Ontario). 
3.2.3 Cell growth and viability 
Cell growth and viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) reduction assay 
(Promega, Madison, WI), according to the manufacturer’s protocol and as previously described 
[57, 58]. Cells were seeded in 96-well plates and treated with compound for 72 h. Optical density 
was measured at 490 nm. Cell viability was also assessed by Annexin V and PI (ANN/PI) 
staining (Biovision, Mountainview, CA) and flow cytometry, as previously described [58]. 
3.2.4 Nutraceutical screen 
Nutraceuticals were obtained from commercial sources (NeaLanders Inc., Frutarom, 
Matreya and Sequoia Chemical Inc.). The unique nutraceutical library was created and screened 
similar to previously described methods [57-59]. Briefly, AML cells (1.5 × 104/well) were 
seeded in 96-well polystyrene tissue culture plates. After seeding, cells were treated with aliquots 
(10 µM final concentration) of library compound with a final dimethyl sulfoxide (DMSO) 
concentration of less than 0.05%. After 72 h, cell growth and viability were measured by the 
MTS assay. 
3.2.5 Cytosolic calcium measurements 
Cytosolic calcium was measured using fluo-3AM, which is a highly charged fluorescent 
dye that accumulates in the cytosol and emits green fluorescence following subsequent binding 
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of calcium ions, similar to methods described previously [60]. Briefly, a stock solution of 1 mM 
fluo-3AM was diluted to 5 µM in fluo-3AM loading buffer (10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 137 mM NaCl, 5nM KCl, 1 mM Na2HPO4, 5 mM 
glucose, and 0.5 mM MgCl2 (pH 7.4)). Treated cells (with glucopsychosine or vehicle control) 
were incubated with fluo-3AM for 30 min at 37 °C with gentle agitation. After incubation, cells 
were washed twice in a calcium estimation buffer (fluo-3AM loading buffer and 1 mM CaCl2) to 
remove and inactivate any extracellular fluo-3AM. Cells were then incubated with propidium 
iodide (PI) for 15 min at room temperature. The shift in green fluorescence was measured by 
flow cytometry (Guava 8HT; EMD Millipore, Billerica, MA). Cytosolic calcium was quantified 
by taking the mean fluorescence values of live gated cells and normalizing them to the zero 
control. 
3.2.6 Western blotting 
Whole cell lysates were prepared from treated cells, heated for 5 min at 95 °C, and 
subjected to gel electrophoresis on 7.5% SDS–polyacrylamide gels at 150 V for 85 min. The 
samples were then transferred at 25 V for 45 min to a PVDF membrane and blocked with 5% 
milk in Tris-buffered saline-tween (TBS-T) for 1 h. The membrane was incubated with the 
primary antibody, PARP-1 or calpain antibody (1:1000; Santa Cruz Biotechnologies), overnight 
at 4 °C. Membranes were then washed and incubated with the appropriate secondary antibody 
(1:10000) for 1 h at room temperature. Enhanced chemiluminescence (ECL) was used to detect 
proteins according to the manufacturer’s instructions (GE Healthcare; Baie d’Urfe, Quebec) and 
luminescence was captured after 5 min using the Kodak Image Station 4000MM Pro and 
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analyzed with a Kodak Molecular Imaging Software Version 5.0.1.27. All membranes were 
stained with Ponceau S and imaged to ensure equal loading, as described by Dam et al. [61]. 
3.2.7 Calpain activation assay 
The Calpain-Glo Protease Assay (Promega, Madison, WI) was used to measure calpain 
activity through luminescence. A proluminescent calpain substrate was added to treated cells in 
white-walled, 96-well plates and measured at 10 min intervals according to manufacturer’s 
instructions. The experiment was performed in triplicate with the mean luminescence value and 
standard deviation shown for each sample treatment. 
3.2.8 Xenograft animal model 
NOD/SCID (N = 24, Jackson Laboratory, Bar Harbor, ME) mice were injected 
subcutaneously in the left flank with OCI-AML2 leukemia cells (2.5 × 106). Mice were then 
randomly assigned to receive glucopsychosine (20 or 40 mg/kg/every other day; in 0.9% NaCl 
and 0.01% tween-80) or vehicle control (0.9% NaCl and 0.01% tween-80) intraperitoneally. 
Tumor volumes (tumor length × width2 × 0.5236) were monitored every other day using a 
caliper. At the end of the experiment (18d), mice were sacrificed by sodium pentobarbital 
injection and cardiac puncture, blood collected and tumors excised and weighed. Blood was sent 
to the Animal Health Laboratory, University of Guelph for blood biochemistry analysis. All 
animal studies were carried out according to the regulations of the Canadian Council on Animal 
Care and with the approval of the University of Waterloo, Animal Care Committee. 
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3.2.9 Interrogation of publically available databases 
The expression profile of the set of known calcium channel genes was assessed in 
publicly available datasets of AML patients compared to normal hematopoietic cells [62]. Mean 
fold-change was computed for the AML vs. normal comparison, and statistical significance 
(>1.25-fold; p < 0.001) was assessed by ANOVA to derive the set of differentially expressed 
calcium channel genes. 
3.2.10 Statistical analysis 
Unless otherwise stated, the results are presented as mean ± SD. Data were analyzed using 
GraphPad Prism 4.0 (GraphPad Software, USA). p ⩽ 0.05 was accepted as being statistically 
significant. 
3.3 Results 
3.3.1 A nutraceutical screen for novel anti-cancer compounds identifies 
glucopsychosine. 
To identify nutraceuticals with anti-cancer activity we compiled a unique library 
consisting of 30 nutraceuticals with previously uncharacterized anti-cancer activity from 
commercially available sources. The library was screened against the AML cell lines, OCI-
AML2 and KG1A, and the “normal” prostate cell line RWPE using the MTS assay following a 
72 h incubation period. The compound which imparted the greatest reduction in viability in both 
AML cell lines without affecting normal cell viability was glucopsychosine (Fig. 4A and B). 
Compound 4 (toosendanin) demonstrated toxicity in all cell lines, including the control cell line, 
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and was therefore not analyzed further and compound 21 is currently being evaluated in our 
laboratory. Glucopsychosine’s activity was validated by generating dose response curves on a 
panel of available AML (n = 3) cell lines using the MTS assay following a 72 h incubation 
period. It reduced the viability in a dose dependent manner in all AML lines tested (Fig. 4C, left 
panel; see Supplementary Table 1 for confirmation of AML surface markers). Cell lines of 
breast, colon and cervical cancer origin were also tested and showed varying degrees of 
sensitivity to glucopsychosine; ALL, CML and myeloma cells were not sensitive and AML cells 
were consistently the most sensitive (Supplementary Fig. 1). Glucopsychosine’s cytotoxicity was 
confirmed using the Annexin/PI assay following 72 h of incubation (IC50: 4.2 ± 0.5 µM; Fig. 
4C, right panel). 
Given the cytotoxicity of glucopsychosine in AML cell lines, we tested its activity in 
primary AML patient samples and in normal hematopoietic cells using the ANN/PI assay. 
Glucopsychosine reduced the viability of primary AML patient samples (n = 3) but had no effect 
on the viability of normal hematopoietic cells (n = 3) (Fig. 4D). Together, these results 
demonstrate glucopsychosine’s selective toxicity toward AML cells. 
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Figure 4. Glucopsychosine is selectively toxic toward AML cells. (A) A screen of our 
nutraceutical library determined that glucopsychosine reduced viability of 2 AML cell lines 
without affecting the viability of RWPE, a “normal” prostate cell line. Compounds were incubated 
with nutraceuticals for 72 h and cell growth and viability were measured by the MTS assay. (B) 
Glucopsychosine’s structure from Schueler et al. [20] (C) (Left panel) AML cell lines were treated 
with increasing concentrations of glucopsychosine for 72 h and cell growth and viability were 
measured by the MTS assay. Data are the mean percentage of viable cells ± SD from three 
experiments. Representative figure is shown. (Right panel) Glucopsychosine’s cytotoxicity was 
confirmed by the Annexin V (ANN)/Propidium Iodide (PI) assay following 72 h of incubation in 
OCI-AML2 cells. Data are the mean percentage of dead cells (i.e., ANN+/PI+) ± SD from 
representative experiments. (D) Normal CD34+bone marrow cells (left panel) and primary AML 
samples (right panel) were treated with increasing concentrations of glucopsychosine for 24 h and 
viability was measured by the ANN/PI assay. *p < 0.05; **p < 0.005; ***p < 0.0001.  
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3.3.2 Glucopsychosine induces caspase-independent apoptosis 
Time course analysis using the ANN/PI assay demonstrated that glucopsychosine-
induced apoptosis (i.e., ANN+/PI−), which was initiated after 12 h of treatment with 10 µM 
glucopsychosine (Fig. 5A, left panel). This apoptotic response was consistent with observations 
that glucopsychosine caused cleavage of poly (ADP) ribose polymerase (PARP) protein, a 
common downstream target of active cysteine proteases (e.g., calpain and caspase-3) [63] (Fig. 
5A, right panel). 
Caspase-3 is a cysteine protease actively involved in apoptosis. To evaluate caspase 
enzyme involvement in glucopsychosine-mediated apoptosis, we blocked caspase activity with 
the pan-caspase inhibitor Z-VAD. However, treatment with 50 µM Z-VAD did not affect 
glucopsychosine’s activity (Fig. 5B, left panel). Interestingly, high Z-VAD concentrations (i.e., 
100 µM) attenuated glucopsychosine’s activity (Fig. 5B, right panel); however, high 
concentrations have been associated with reduced activity of other non-caspase enzymes, 
including calpain [42]. We therefore tested glucopsychosine’s activity in the presence of Q-VD-
OPh, a specific caspase-3 inhibitor. Cell death was not affected following Q-VD-OPh treatment 
suggesting glucopsychosine-induced apoptosis was not dependent on caspase-3 (Fig. 5C, left 
panel). 
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Figure 5. Glucopsychosine induced AML cell apoptosis. (A) (Left panel) Time course analysis 
shows that glucopsychosine (10 µM) induced apoptosis (ANN+/PI−) at 12–24 h. (Right panel) 
Glucopsychosine or control treated cells were incubated for 24 h and cleavage of PARP, a nuclear 
protein participating in DNA repair that is degraded during apoptosis by cysteine proteases (i.e., 
calpain or caspase 3), was measured by Western blotting. Representative blot is shown. (B) AML 
cells were treated with increasing concentrations of glucopsychosine in the presence or absence of 
the pancaspase inhibitor Z-VAD (50 µM, left panel; 100 µM, right panel). Cytarabine was used as 
a positive control and viability was measured by the MTS assay. (C) (Left panel) AML cells were 
treated with increasing concentrations of glucopsychosine in the presence or absence of the 
caspase-3 specific inhibitor Q-VD-OPh for 24 h and cell viability was measured by the ANN/PI 
assay. (Right panel) Jurkat T cells with (Jurk+) or without functional mitochondria (Jurk−) were 
incubated with 10 µM glucopsychosine for 24 h and cell viability was measured by the ANN/PI 
assay. Unless otherwise stated, data are presented as the mean or fold increase compared to 
control ± SD from representative experiments.*p < 0.05; ***p < 0.0001. 
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To exclude mitochondrial involvement, we tested glucopsychosine in Jurkat T leukemia 
cells lacking functional mitochondria, which were generated, as previously described [64, 65] by 
sequential passaging of live cells in media containing 50 ng/ml of ethidium bromide, 100 mg/ml 
sodium pyruvate and 50 µg/ml uridine. Since these cells typically are resistant to apoptosis 
inducing agents [66], we hypothesized that if mitochondria were involved in glucopsychosine-
mediated apoptosis, glucopsychosine-induced death would be abolished in cells lacking 
functional mitochondria. However, as shown in Fig. 5C (right panel), cells without functional 
mitochondria are equally sensitive to glucopsychosine (10 µM). Together, these results show that 
glucopsychosine induces caspase-independent apoptosis. 
3.3.3 Extracellular calcium channels are significantly under-expressed in AML over 
normal cells 
A previous study showed that glucopsychosine-mediated death was a result of changes in 
cytosolic calcium [22]. To probe whether changes in cytosolic calcium could be related to 
glucopsychosine’s AML cell selectivity, we interrogated publicly available gene expression 
profiling datasets [62] for changes in expression of surface calcium channel subunits in AML 
patient samples compared to normal hematopoietic cells. From this analysis, we determined that 
36 different calcium channel genes were significantly under-expressed (p < 0.001, minimum 
fold-change of 1.25) in at least one subtype of AML (M0-M4); only 3 of these would be 
expected to be altered during myeloid differentiation (Supplementary Table 2). Conversely, 28 
calcium channel genes were significantly over-expressed in AML (p < 0.001, minimum fold-
change of 1.25); 11 of these were expected to be over-expressed during myeloid differentiation 
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(Supplementary Table 3). Thus, there is evidence for preferential under-expression of calcium 
channel genes in AML (33 significantly under-expressed genes, compared to 17 significantly 
over-expressed; ratio of nearly 2:1). Together, these results suggest that calcium channels are 
significantly down-regulated in AML cells. 
3.3.4 Glucopsychosine increases intracellular calcium to induce calpain-mediated 
apoptosis 
Given our finding that calcium surface channels are significantly dysregulated in AML, 
we next assessed whether glucopsychosine’s AML activity was related to changes in cytosolic 
calcium levels using the fluorescent dye fluo-3AM. A 2–3-fold increase in cytosolic calcium 
(i.e., shift in fluorescent intensity) was observed in glucopsychosine treated cells between 4 and 
8 h of incubation (i.e., prior to the onset of apoptosis) (Fig. 6A, left and right panels). 
Since increases in cytosolic calcium can induce apoptosis through activation of the 
calcium-dependent cysteine protease calpain, we next assessed whether glucopsychosine 
activated calpain enzymes. AML cells were incubated with 10 µM glucopsychosine for 
increasing durations and calpain activation was determined using a commercially available 
luminescent calpain activation assay. Consistent with the observed increases in intracellular 
calcium, calpain activity was significantly increased compared to vehicle control between 6 and 
8 h of incubation (Fig. 6B, left panel: *p < 0.05). Protein levels of active calpain in 
glucopsychosine treated leukemia cells were also detected using Western blot analysis (Fig. 6B, 
middle panel). To confirm the importance of calpain in glucopsychosine-mediated cell death, 
AML cells were co-incubated with the calpain inhibitor MDL28170. Treatment with the calpain 
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inhibitor abolished glucopsychosine-mediated AML cell death (Fig. 6B, right panel, *p < 0.001) 
and apoptosis (Appendix 4). These results demonstrate that active calpain is functionally 
important for glucopsychosine’s toxicity. 
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Figure 6. Glucopsychosine increased cytosolic calcium and activated calpain enzymes. (A) 
(Left panel) AML cells incubated with 10 µM glucopsychosine or vehicle control for increasing 
duration showed increases in cytosolic calcium, as measured by the intracellular calcium selective, 
fluorescent dye fluo-3AM and flow cytometry. Cytosolic calcium was determined by quantifying 
the shift in green fluorescence compared to control. Representative histograms are shown. (Right 
panel) Graphical representation demonstrating the cytosolic calcium increase. (B) (Left panel) 
Calpain activity was measured in control or glucopsychosine treated AML cells using a 
commercially available kit as outlined in the Methods. Cells were also co-incubated with a calpain 
inhibitor MDL28170 (MDL). (Middle panel) Protein levels of active calpain (MW = 60 kDa) were 
also measured in these cells by Western blotting. Representative blots are shown. (Right panel) 
Glucopsychosine was co-incubated with MDL for increasing duration and cell death was measured 
by the ANN/PI assay. Unless otherwise stated, data are presented as the mean or fold increase 
compared to control ± SD from representative experiments.*p < 0.05; **p < 0.005; ***p < 0.0001. 
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3.3.5 Glucopsychosine-induced apoptosis is mediated by extracellular calcium and not 
intracellular stores 
Calcium can enter the cytosol from the extracellular matrix via surface calcium channels 
or through intracellular calcium stores such as the mitochondria or endoplasmic reticulum [36, 
67]. To determine the source of glucopsychosine-mediated increases in cytosolic calcium, we 
first co-incubated leukemia cells with verapamil, cyclosporin A, or TMB-8, which block 
increases in cytosolic calcium mediated by L-type plasma membrane channels, mitochondria or 
endoplasmic reticulum, respectively [68-70]. Only verapamil abrogated glucopsychosine-induced 
increases in cytosolic calcium and apoptosis, suggesting that the source of calcium in 
glucopsychosine-mediated AML cell death is from the extracellular space (Fig. 7A, left and right 
panel; and Supplementary Fig. 2). Moreover, our results demonstrating glucopsychosine’s 
activity is unchanged in cells lacking mitochondria further exclude mitochondrial involvement in 
glucopsychosine-mediated death (Fig. 7C, right panel). To confirm that the extracellular space 
was the source of glucopsychosine-mediated increases in cytosolic calcium, glucopsychosine’s 
ability to induce death was assessed in calcium-free media. Since basal levels of death increased 
when our AML cells were incubated in calcium-free media, we performed these experiments 
using shorter incubation times at higher glucopsychosine concentrations (i.e., 20 µM, 1 h). Here, 
AML cells were suspended in PBS, in the absence and presence of high glucopsychosine 
concentrations, and cell death was evaluated after 1 h by the Annexin/PI assay.  
Glucopsychosine’s activity was abolished in calcium-free media (Fig. 7B, left). Moreover, no 
increases in cytosolic calcium were observed following treatment in calcium-free media (Fig. 7B, 
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right panel). Together, these results indicate that the source of glucopsychosine-mediated 
increases in cytosolic calcium is from the extracellular space. 
0 30 60
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Regular Media
Ca2+ Free Media
***
***
Time (min)
F
o
ld
 i
n
c
re
a
s
e
C
y
to
s
o
li
c
 C
a
 2
+
0 2 4 8
0.0
0.5
1.0
1.5
2.0
2.5
3.0 GLU + VER 0 M
GLU + VER 100 M **
***
Time (hr)
F
o
ld
 i
n
c
re
a
s
e
C
y
to
s
o
li
c
 C
a
 2
+
a
b
0 30 60
0
10
20
30
40
50
60
70
Regular Media
Ca2+ Free media
*** **
Time (min)
%
 D
e
a
d
 (
A
N
N
+
/P
I+
)
0 10 20
0
10
20
30
40
50
60
70
VER 0 M
VER 100 M ******
GLU [M]
%
 D
e
a
d
 (
A
N
N
+
/P
I+
)
 
Figure 7. The extracellular space is the source of glucopsychosine-mediated increases in 
cytosolic calcium. (A) (Left panel) AML cells were incubated with increasing concentrations of 
glucopsychosine for 24 h in the absence or presence of verapamil (VER). Cell death was measured 
using the ANN/PI assay. (Right panel) Cytosolic calcium was measured in AML cells treated with 
glucopsychosine (10 µM) in the absence or presence of verapamil as described in the Methods 
section using the fluorescence indicator, fluo-3AM. (B) (Left panel) AML cells were cultured in 
regular or calcium-free media with 20 µM glucopsychosine for increasing duration. Cell death was 
measured by the ANN/PI assay. (Right panel) Increases in cytosolic calcium were measured in 
AML cells treated with 20 µM glucopsychosine in normal or calcium free media as described in 
the Methods section using the fluorescence indicator, fluo-3AM. Unless otherwise stated, data are 
presented as the mean or fold increase compared to control ± SD from representative 
experiments. **p < 0.005; ***p < 0.0001. 
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3.3.6 Glucopsychosine delays tumor growth and reduces tumor weights in leukemia 
mouse xenografts 
Given glucopsychosine’s in vitro activity, we next tested its activity in vivo. Here, OCI-
AML2 cells were subcutaneously injected into the left flank of NOD/SCID mice. Mice were then 
intraperitoneally treated every other day with 20 or 40 mg of glucopsychosine/kg body weight or 
a PBS vehicle control. Compared to control treated mice, both concentrations of glucopsychosine 
delayed tumor growth (Fig. 8A; left panel) and reduced tumor weights upon sacrifice (Fig. 8A; 
right panel). In addition, analysis of hematoxylin and eosin stained tissue sections demonstrated 
decreased cellular density in tumors of animals treated with glucopsychosine indicating cell 
death in the tumor following drug treatment (Supplemental Fig. 3). 
To assess glucopsychosine’s toxicology, blood was collected upon sacrifice and analyzed 
for levels of alkaline phosphatase or creatine kinase, markers of kidney and liver function, 
respectively [71]. There were no differences in blood biochemistry makers following 
glucopsychosine treatment (Fig. 8B). In addition, mouse body weights were unchanged between 
control and glucopsychosine treated mice throughout the duration of the experiment (Fig. 8B). 
Finally, complete blood count analysis showed no differences in red blood cell counts or 
hemoglobin concentrations between glucopsychosine and control treated mice (Fig. 8B). Taken 
together, these results show that glucopsychosine imparts anti-tumor activity without toxicity. 
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Figure 8. Glucopsychosine delayed tumor growth and reduced tumor weight in leukemia 
mouse xenografts without imparting toxicity. NOD/SCID mice were subcutaneously injected 
with OCI-AML2 cells (n = 24; 8/group) and following implantation were treated intraperitoneally 
with 20 or 40 mg/kg glucopsychosine or a PBS control every other day for 18 days. Tumor volume 
and body weights were measured every other day. At the termination of the experiment, mice were 
sacrificed, blood was collected and tumors were excised and weighed. (A) Glucopsychosine 
significantly delayed tumor growth (left panel, *p < 0.05, 0 vs. 40 mg/kg) and reduced tumor 
weights (right panel; *p < 0.05). (B) Glucopsychosine treated mice had no changes in serum levels 
of alkaline phosphatase or creatine kinase, which are markers of kidney and liver damage, 
respectively, or changes in body weight, red blood cell counts or hemoglobin concentrations 
compared to control treated animals. 
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3.4 Discussion 
A screen of a nutraceutical specific library identified glucopsychosine as a novel agent 
with activity against AML. We determined that AML cells display dysregulated expression of 
calcium surface channels and that glucopsychosine increased cytosolic calcium, the source of 
which was the extracellular space, to induce calpain-mediated apoptosis. Our work with mouse 
xenograft models further demonstrated that glucopsychosine imparts anti-leukemia activity 
without toxicity. 
Glucopsychosine was selectively toxic toward AML over normal cells and imparted in 
vivo anti-tumor activity without toxicity. The exact mechanism of this specificity is unknown; 
however, we hypothesize it is related to several features of AML cells. First, interrogation of 
publically available AML gene expression databases indicated that surface receptors regulating 
cytosolic calcium levels are significantly under-expressed in AML cells compared to normal 
cells. This observed pattern of reduced surface calcium channel expression is similar to other 
disease states such as atrial fibrillation [72], colonic inflammation [73] and cerebral ischemia 
[74]. Although the physiological consequence of this under-expression in AML cells is not 
known, reduced calcium channel expression was associated with delayed neuronal death 
following tissue hypoxia [74]. It is therefore possible that AML cells under-express extracellular 
calcium channels to increase survival, as this would prevent increases in cytosolic calcium that 
would otherwise result in activation of apoptotic cell death. In support of this hypothesis, ER 
calcium concentrations are reduced in AML compared to normal cells [75]. This suggests that 
AML cells tightly control their stored intracellular calcium levels to limit increases in cytosolic 
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calcium. Therefore, a likely component of glucopsychosine’s selectively is related to its ability to 
increase cytosolic calcium via calcium surface channels; however, future studies are needed to 
confirm which extracellular channel(s) (i.e., voltage or ligand dependent) are specifically 
involved in glucopsychosine’s activity. 
A second feature of AML cells that would render them sensitive to glucopsychosine is the 
recent observation that calpain levels are significantly elevated while calpastatin, a calpain 
inhibitor, is significantly reduced in AML cells compared to normal hematopoietic cells [44]. 
Calpain enzymes are activated by increases in cytosolic calcium and, similar to caspase enzymes, 
are cysteine proteases that induce apoptosis by degrading cellular substrates [40]. In AML cells 
with high basal calpain levels and reduced calpastatin, additional activation of these enzymes 
could overcome a threshold and induce apoptosis. This is seen in other disease states 
characterized by elevated basal caspase 3 levels (i.e., Breast cancer, Parkinson’s disease and 
Celiac disease) where the application of a death stimulus results in caspase-dependent cell death 
[76-78]. We therefore propose a similar mechanism whereby glucopsychosine’s mechanism of 
AML selectivity is also related to its ability to further activate calpain enzymes resulting in 
apoptotic cell death. 
In our study, increased levels of cytosolic calcium and extracellular calcium were 
functionally important for glucopsychosine-induced AML cell apoptosis. The increase in 
cytosolic calcium occurred 4–8 h following glucopsychosine treatment, which is consistent with 
other studies reporting slower increases in cytosolic calcium when the calcium originates from 
the extracellular space [79, 80]. Increased cytosolic calcium resulted in calpain activation. 
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Blocking calpain activation abolished glucopsychosine-mediated apoptosis highlighting the 
functional importance of calpain in glucopsychosine-induced AML cell death. Calpain activation 
can result in caspase-3-dependent or independent apoptosis. Calpain-mediated, caspase-3-
dependent apoptosis requires mitochondrial proteins [36]. However, since death occurred in cells 
lacking mitochondria and in the presence of caspase inhibitors, our results suggest that 
glucopsychosine-induced AML apoptosis is calpain-mediated and caspase-independent. This 
mode of death may be particularly important to a subset of AML patients, as it was recently 
shown that calpain levels in AML cells may be an important prognostic indicator. Niapour et al. 
(2012) showed that patients samples with elevated cellular calpain levels had no response to 
PD150606 (a calpain inhibitor) whereas patient samples with low calpain levels were associated 
with improved complete response rates [44]. Thus, application of a stimulus to increase calpain 
in AML cells with already elevated calpain would be a novel approach at inducing a response in 
these patients, which do not respond to conventional therapy. This represents a novel area in 
AML therapeutics, as no current clinical AML drug activates this pathway. 
Glucopsychosine or glucosylsphingosine is a glycosylated sphingosine (Fig. 4B). It can 
be synthesized chemically or derived from the milk fat globule membrane and is found in bovine 
milk at concentrations of 0.067 g/L (0.15 µM) [81]. Since glucopsychosine concentrations 
needed to impart anti-leukemia activity would not be achievable following milk or dairy product 
consumption, glucopsychosine would need to be administered as a nutraceutical, likely in 
intravenous form. Future studies are needed to assess glucopsychosine’s pharmacokinetics 
following oral dosing. Nutraceuticals are bioactive compounds isolated from food, concentrated 
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and sold in pill or liquid form and are a subset of a larger family of compounds known as natural 
health products. There are an estimated 25 000 different nutraceutical compounds, with only a 
relative few having reported anti-cancer treatment properties [16]. Here, we report for the first 
time, that the milk-derived glucopsychosine is a novel nutraceutical with activity against AML. 
There is little existing human pharmacokinetic or safety data on glucopsychosine. Although 
several in vitro studies report toxicity following exogenous administration to rat hepatocytes and 
erythrocytes [82] and human and mouse neurons in culture [20, 21], there are limited human 
or in vivo animal studies reporting glucopsychosine pharmacokinetics or toxicology. Our results 
show that at double the glucopsychosine concentrations needed to reduce leukemia tumor growth 
(i.e., 40 mg/kg), there were no effects on mouse body weight; or on serum levels of alkaline 
phosphatase and creatine kinase, which are markers of kidney and liver damage, respectively 
[71]; or changes in red blood cell counts or hemoglobin levels. However, a limitation to our in 
vivo work is that a tumor regression model was not used. Thus, future studies would be needed to 
address whether glucopsychosine is able to regress an already established tumor. Nonetheless, 
our data in primary samples show that glucopsychosine is selectively toxic toward AML patient 
cells while not affecting normal cell viability. Together, these results suggest a potentially wide 
therapeutic window for glucopsychosine. Interestingly, plasma glucopsychosine levels are 
significantly elevated in patients with Gaucher’s Disease [83]. This is a lysosomal storage 
disorder caused by a deficiency in the enzyme glucocerebrosidase that results in cellular 
accumulation of glucosylceramide, the deacetylated precursor of glucopsychosine [84]. The lipid 
filled cells, mostly macrophages, accumulate in liver, spleen and bone marrow resulting in 
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hepatosplenomegaly, pancytopenia and bone pain as well as causing possible neurological 
symptoms such as convulsions and muscle twitches [85]. The physiological consequence of 
plasma glucopsychosine levels is unknown; however, the aforementioned study showed no 
correlation between plasma concentrations and disease severity even though plasma 
glucopsychosine levels were 200-fold greater in Gaucher patients than normal controls [83]. The 
lack of association between plasma levels and toxicity suggests that plasma glucopsychosine 
does not impart toxicity. Nonetheless, given the limited human data, future studies are needed to 
carefully assess glucopsychosine’s pharmacokinetics and safety. 
In summary, a screen of a unique, in-house nutraceutical library identified 
glucopsychosine, a bovine milk-derived lipid, as a novel compound capable of inducing calpain-
mediated AML cell apoptosis. Surface calcium channels are significantly under-expressed in 
AML cells and the extracellular space was the source of glucopsychosine-mediated increases in 
cytosolic calcium. This provides a unique mechanism of selectivity by which glucopsychosine 
induces AML cell apoptosis. Future studies are needed to determine which of the surface calcium 
channels may be affected by glucopsychosine and clinical studies are needed to evaluate 
glucopsychosine’s safety. 
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Supplemental figure 1: Glucopsychosine in non-AML cell lines. A panel of solid tumor 
(HCT116, HeLa, MDA468), myeloma (MY5, LP1, KMS11), ALL (Jurkat), and CML (K562) cell 
lines were treated with increasing concentrations of glucopsychosine for 72 hours and cell growth 
and viability were measured by the MTS assay. Data are the mean percentage of viability cells ± 
SD from representative experiments. 
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Supplemental figure 2: Glucopsychosine in the presence of inhibitors of intracellular calcium 
release. AML cells were incubated with 10µM glucopsychosine for 24 hours in the absence or 
presence of TMB-8 or cyclosporine. Viability was measured by the ANN/PI assay.  
 
 
 
 
Supplemental figure 3: Hematoxylin and eosin stained tumor sections x200. Tumors from each 
treatment group were sectioned and stained with hematoxylin and eosin. Three representative 
images from each treatment group are presented at x 200 magnification (Group 1 – PBS; Group 2 
– 20 mg/kg GLU; Group 3 – 40 mg/kg GLU).    
  44 
Supplementary Table 1: AML surface markers.  The myeloid markers (CD123+ and 
CD33+/CD19-) were tested to confirm the nature of our cell lines. 
 
Cell line %CD33+/19- %CD123+ 
AML2 85.2 75.8 
KG1a 91.2 79.5 
U937 85.8 79.2 
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CHAPTER 4:  EXPERIMENTAL RATIONALE 
The purpose of this chapter is to provide rationale for the experiments used in this thesis.    
The following expanded methods are in addition to those listed in Chapter 3. 
4.1 Materials and methods 
4.1.1 MTS cell viability assay 
The MTS cell viability assay measures the ability of viable cells to metabolize NADPH-
dependent cellular oxidoreductase enzymes which produces a formazan product that is purple.  
The amount of formazan formed will give an indication of the number of metabolizing cells 
when absorbance is read and compared to control wells.  In these experiments, 95 µL of cells per 
well are seeded in 96 well plates at a concentration at which when ready to read (eg. 24 or 72 
hours later) the amount of cells per well will be at 90% confluency.  5 µL of drugs or vehicle 
control are added to each well and incubated. 20 µL of 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) reduction assay 
(Promega, Madison, WI) is added directly to the 96 well plate and incubated at 37°C for 2-3 
hours at which then the optical density is read at 490nm.   
4.1.2 Flow cytometry and Annexin V/propidium iodide (PI) viability assay 
Flow cytometry assays were performed on the Guava easyCyte 8HT Bench top Flow 
Cytometer (Millipore, Billerica, MA) and GuavaSoft 2.2.3 (Millipore) flow cytometry software.  
All assays were performed in 96 well plates with appropriate unstained and single-stain controls 
to set basal thresholds and compensate for multi-stain bleeding.  Annexin V/propidium iodide 
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(ANN/PI) staining was used to determine cell viability (ANN-/PI-), early apoptosis (ANN+/PI-), 
and cell death (ANN+/PI+). A mastermix solution was made combining 250 µL of Annexin V 
Binding Buffer (BD Pharmingen), 1 µL of 150 µg/mL Annexin V (Biovision) and 2.5 µL of 250 
µg/mL PI (Biovision) per sample.  Treated cells were spun down and resuspended in 250 µL of 
mastermix solution and incubated for 20 minutes at room temperature in the dark prior to 
collection and analysis via flow cytometry. 
4.1.3 Caspase 3/7 assay 
Apo-ONE® Homogeneous Caspase-3/7 (Promega) was purchased and performed 
according to manufacturer’s protocol.  50 µL of Apo-ONE homogenous caspase-3/7 reagent was 
added to 50 µL of blank, control (Doxorubicin treated cells, Sigma-Aldrich) or glucopsychosine 
treated cells and mixed at 300-500 rpm for 30 seconds in white-walled 96 well plates.  Samples 
were incubated for 1 hour in the dark at room temperature.  Fluorescence was measured at an 
excitation wavelength range of 499 nm and an emission wavelength of 521 nm. 
 
4.1.4 Western blotting 
Whole-cell lysate preparation 
 
Treated cells were collected and incubated with chilled RIPA buffer (Sigma-Aldrich) 
supplemented with protease inhibitors (Sigma-Aldrich) in a 2:1 ratio.  Cells were vortexed 
continuously for 20 minutes or until lysed.  Protein was collected by centrifuging lysed cells at 
13,200 RPM for 20 minutes at 4°C and collecting the supernatant.   
  47 
BCA protein assay and sample preparation 
 
The BCA protein assay was used to measure total protein content. Bovine serum albumin 
(BSA; Sigma-Aldrich) diluted in distilled water generated a standard curve and was used to 
determine total protein content of each sample of lysate.  Prior to taking absorbance readings, 
200µL of bicinchoninic acid (BCA) working agent was added to each sample (50 parts BCA:1 
part copper II sulfate; Sigma-Aldrich) and incubated for 30 minutes at 37°C. OD was then 
measured at 527nm using a spectrophotometer and values were plotted on against the standard 
curve.  Values from the BCA protein assay were used to prepare samples containing 30-50μg 
total protein, with 1/6 sample buffer (240 mM Tris-HCl at pH 6.8, 6% w/v SDS, 30% v/v 
sucrose, 0.02% w/v bromophenol blue, and 50 mM DTT) volume and lysis buffer to a total 
volume of 30μl. Prior to well loading, samples were heated at 95°C for 5 minutes and spun for 3 
seconds to collect protein sample. 
SDS-PAGE and immunodetection of target proteins 
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins based on size.  Samples were loaded into 10% - 15% polyacrylamide gels and 
separated using a Mini Trans-Blot Cell (Bio-Rad, Hercules, CA) in electrophoresis buffer (25 
mM Tris base, 190 mM glycine, 3.5 mM sodium dodecyl sulfate) at 150 V for 1 hour.  The 
proteins are then transferred onto a PVDF membrane (Bio-Rad) in transfer buffer (25 mM Tris 
base, 190 mM glycine, 20% v/v methanol) using a Trans-Blot semi-dry transfer cell at 25 V for 
45 min. 
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PVDF membranes were then blocked with 5% BSA in Tris-buffered saline (20 mM Tris 
base, 150 mM NaCl, pH 7.6) plus 0.1% Tween (TBS-T) for 1 hour or overnight at 4°C.  
Blocking solution was discarded and primary antibodies (Table 1) were incubated with the 
membranes for 1 hour or overnight at 4°C.  Membranes are washed and incubated with 
corresponding secondary antibody for 1 hour at room temperature.  Enhanced 
chemiluminescence (ECL) was used to detect proteins according to the manufacturer’s 
instructions (GE Healthcare; Baie d’Urfe, Quebec) and luminescence was captured after 5 min 
using the Kodak Image Station 4000MM Pro and analyzed with a Kodak Molecular Imaging 
Software Version 5.0.1.27. All membranes were stained with Ponceau S and imaged to ensure 
equal loading, as described by Dam et al. [61]. 
Table 1. Antibodies 
Antibody Isotype MW (kDa) Concentration Manufacturer 
Calpain Mouse 60 1:1000 Santa Cruz Biotechnology 
Caspase 12 Rat 50, 40 1:200 Santa Cruz Biotechnology 
Cytochrome c Rabbit 14 1:1000 Cell signaling technology 
GRP78 Goat 78 1:400 Santa Cruz Biotechnology 
PARP Rabbit 89, 116 1:1500 Cell signaling technology 
 
4.1.5 Cell cycle analysis 
Prior to cell cycle analysis, cells were treated with 1, 5, or 10 µM glucopsychosine 
(Matreya), 0.01 or 1 µM nocodazole (Sigma-Aldrich), or 0.2% DMSO (Sigma-Aldrich) and 
incubated for 24 hrs.  Afterwards, 0.5×106 KG1a cells were collected and washed with ice cold 
PBS (Sigma-Aldrich) and fixed with 200 µL of 100% ethanol for 1 hr at -20°C.  The fixed cells 
were thawed and washed in ice cold PBS and then diluted to a concentration of 1x105 cells/ml in 
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ice cold PBS. Each sample was then incubated for 30 minutes at 37°C with DNase-free RNase A 
(Sigma-Aldrich) at a final concentration of 5μg/ml. Lastly, PI was added at a final concentration 
of 50μg/ml and incubated for 15 minutes at room temperature in the dark. The samples were 
analyzed with the Guava Cell Cycle Software Module. 
4.1.6 Tubulin polymerization 
Purified bovine tubulin (1.8 mg/mL; Cytoskeleton) was added to ice-cold polymerization 
buffer (PEM: 80mM PIPES, 0.5mM EGTA, 2mM MgCl2, 10% glycerol, and 1mM GTP) and 
centrifuged for 5 minutes at 4°C at top speed in a microcentrifuge to collect the supernatant. 5 µL 
of controls (PBS, Paclitaxel, nocodazole; Sigma-Aldrich) or glucopsychosine, were plated in 96-
well plates and 95 µL of supernatant (containing tubulin) was added. Immediately after the 
addition of tubulin, the plate was placed in the spectrophotometer, which was maintained at 
37°C, and the absorbance measured every 2.5 minutes for 1 hour at 340 nm. 
4.1.7 Establishing a xenograft tumor model 
As a prerequisite to performing our in vivo studies with glucopsychosine, we investigated 
which human myeloid leukemia cell lines were able to induce xenograft tumors in non-obese 
diabetic severely combined immunocompromised (NOD/SCID) mice (Appendix 5).  The cells 
lines tested were KG1a, TEX, OCI-AML2, and U937.  Eight NOD/SCID mice were split into 
two groups of four and marked by ear notching.  On day 1, Group 1 mice were injected 
subcutaneously above the left hind leg with 1×106 KG1a cells.  Group 2 mice were injected in 
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the same fashion, but with TEX cells, 1×106 and 0.5×106.  The mice were monitored three times 
a week for the presence of xenograft tumors which should be present 10-17 days post injection. 
By day 23, tumors were still not present in any of our mice so we performed another set 
of injections.  Two mice from Group 1 received an increased number of KG1a cells injected 
(10×106 cells) and the remaining two mice received 1x106 cells.  On day 30, Group 2 mice 
received two alternate cell lines (U937 and OCI-AML2) in place of the TEX cell line.  U937 and 
OCI-AML2 cells were injected above the right and left hind leg respectively at 10×106 and 5×106 
cells.  By day 37, OCI-AML2 tumors were present. 
Tumor lengths and widths were measured with an electronic caliper and tumor volumes 
were calculated with the equation: width2 × 
length
2
.  Measurements at day 39 showed excessive 
tumor growth past our designated endpoint (1000 mm3) and the 10×106 OCI-AML2 mice were 
sacrificed immediately via cardiac puncture.  Mice 6 and 7 (OCI-AML2 at 5×106 cells) showed a 
slower tumor growth progression and reached end point at day 50 and day 44 respectively.  
Finally, Group 1 NOD/SCID mice injected with KG1a started to grow tumors at day 44, twenty-
one days after the second round of injections.  All mice were sacrificed via cardiac puncture and 
tumors were harvested.  OCI-AML2 cells injected at 5×106 cells per mouse was sufficient to 
grow tumors.  All animal studies were carried out according to the regulations of the Canadian 
Council on Animal Care and with the approval of the University of Waterloo, Animal Care 
Committee. 
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4.2 Results 
The initial screen (Fig. 4A) was performed by Dr. Spagnuolo at the University of 
Waterloo, School of Pharmacy.  Glucopsychosine was selected because it fulfilled the criteria 
explained in Ch. 3.3.1.  Eric Lee further assessed glucopsychosine’s ability to reduce cell 
viability in multiple cell lines with the MTS assay and Annexin V/PI cell viability assay.  The 
dose response curve (Ch. 3.8 Supp. Fig. 1) exhibited glucopsychosine’s ability to inhibit cell 
growth of multiple cancerous cell lines (HCT116, HeLa, MDA468, MY5, LP1, KMS11, Jurkat, 
and K562).      
4.2.1 The intrinsic pathway of apoptosis 
The intrinsic pathway of apoptosis involves the loss of mitochondrial membrane potential 
which releases executioner proteins of apoptosis [26].  The generation of reactive oxygen species 
(ROS) can initiate this apoptotic pathway.  Antioxidants such as N-acetyl-cysteine (NAC) can be 
used to neutralize the effects of ROS, thereby protecting the cells [86].  To investigate this 
pathway, AML cells were incubated with glucopsychosine or glucopsychosine + NAC and cell 
viability was measured by the MTS assay (Fig. 9A). 
The results from this experiment showed that co-treatment with NAC abrogated cell 
death in KG1a cells suggesting that NAC could be protecting the cells from ROS cytotoxicity.  
As shown in Ch. 1.3.2 Figure 2, increases in ROS can lead to loss of mitochondrial membrane 
potential, which leads to the release of cytochrome c and the eventual downstream activation of 
caspase 3 [33].  Caspase 3 targets many cellular substrates directly resulting in cell apoptosis.  To 
determine if executioner caspases were activated to induce glucopsychosine-mediated apoptosis, 
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a caspase 3/7 activation assay was done by Eric Lee (Fig. 9B).  The results from this experiment 
showed an insignificant increase in caspase 3/7 activation in cells treated with glucopsychosine 
(ANOVA (F(3,4) = 5.897, p > 0.05, r = 0.8156).  This experiment marked the end of the 
preliminary data collected prior to my taking over of the project.  
The next experiment we did was to look for cytochrome c release from the mitochondria. 
Western blots showed no increases in cytochrome c protein levels with increased 
glucopsychosine exposure (Fig. 9C).  If the mitochondrial pathway was being activated by 
glucopsychosine, cytochrome c levels should have increased with glucopsychosine exposure.  To 
confirm that the mitochondria was not an integral part of glucopsychosine-mediated cell death, a 
Jurkat cell line lacking functional mitochondria was used as described in Ch. 3.3.2 Fig. 5C.  This 
cell line was still sensitive to glucopsychosine treatment which confirmed that mitochondria were 
not an essential part of glucopsychosine-mediated cell death.   
Finally, through literature review of the MTS assay, we found that this assay should not 
be used when assessing anti-oxidizing agents because they are prone to give false positive results 
[87, 88].  Given this experimental limitation, it is likely that NAC gave a false positive result and 
did not block glucopsychosine-cell death.  Thus, ROS is likely not functionally important in 
glucopsychosine-mediated death. 
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Figure 9. Assessing the intrinsic mitochondrial pathway of apoptosis. (A) N-acetyl-cysteine 
and the MTS assay.  KG1a cells were incubated with increasing concentrations of glucopsychosine 
and cell viability was assessed via the MTS assay to determine if incubation with NAC would 
abrogate cell death. (B) Caspase 3/7 activation assay with glucopsychosine for 24 hr. Caspase 3 
and 7 substrates were introduced into the cells with a luminescent probe that produces a signal 
when cleaved by caspase 3 or 7. The relative intensity was recorded and compared. Doxorubicin 
was used as a positive control and glucopsychosine at 0 µM was a negative control. (C) Western 
blot of cytochrome c protein in U937 and OCI-AML2 cell lines. Cytochrome C (15 kDa) was 
Western blotted for in two different AML cell lines treated with 10 µM glucopsychosine at 0, 2, 8, 
and 24 hours. Ponceau staining was used to quantify equal loading of samples.  ***p < 0.0001 
 
4.2.2 The cell cycle 
A defining attribute of cancerous cells is their ability to overcome cell cycle signal 
checkpoints and continuously divide [89].  Indeed, many anti-cancer drugs inhibit the cell cycle 
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at specific stages.  These agents can target DNA directly, DNA regulatory machinery, DNA 
synthetic proteins, or cell cycle machinery such as microtubules to cause cell cycle arrest [90, 
91]. Anti-cancer drugs are generally classified based on which phase of the cell cycle they act on.  
Broadly, these cytotoxic agents can be cell cycle specific (CCS) or cell cycle non-specific 
(CCNS).  CCS drugs are selective to cells that have high turnover rates (such as blood cells) 
because these cells cycle through phases more frequently than non-dividing cells (such as 
neuronal cells).  To investigate if glucopsychosine affected the cell cycle, we performed a cell 
cycle analysis in KG1a cells incubated with glucopsychosine at increasing concentrations.  
Nocodazole was used as a positive control because it interferes with microtubule polymerization 
and arrests cells in the G2/M phase (Fig. 10A) [92].  The results from this experiment showed 
that cell cycle was being arrested during the G2/M phase when treated with 10 µM 
glucopsychosine for 24 hrs.  This result was similar to the nocodazole control, therefore, 
microtubule polymerization was assessed next.   
Tubulin is an essential cytoskeletal protein that polymerizes to form microtubules that are 
important for structural and functional purposes [93].  Tubulin activity is dependent on its 
dynamic characteristics where it dimerizes and polymerizes to perform its function, which 
includes participation in cell division (mitotic spindle), cell movement and transportation [93].  
Drugs can alter polymerization of microtubules by either stabilizing polymerization or favouring 
depolymerization of tubulin subunits.  Paclitaxel promotes tubulin polymerization by stabilizing 
the microtubule polymer and preventing disassembly of the lagging end [94].  This is cytotoxic 
to cells because cells cannot form proper spindle fibres which will inhibit mitosis.  In contrast, 
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nocodazole alters tubulin polymerization by destabilizing microtubules and favouring 
disassembly of tubulin subunits which has similar devastating effects [92].   
In this experiment, nocodazole was used as a positive control for depolymerization and 
paclitaxel was used as a positive control for increased polymerization.  An untreated sample was 
used to represent normal tubulin polymerization.  Purified tubulin was kept on ice until ready to 
be plated on 96 well plates in which the drugs were previous loaded and absorbance readings 
were taken every 2.5 minutes.  As tubulin polymerizes, OD340 nm readings also increase until 
reaching a saturation point.  The samples were treated with glucopsychosine at 50 or 100 µM to 
ensure a response ensued (Fig. 10B).  
The results from the experiment showed no significant increase or decrease in the rate of 
tubulin polymerization with glucopsychosine treatment.  We concluded from this that tubulin 
targeting was not glucopsychosine’s mechanism of action.  
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Figure 10. Cell cycle arrest and tubulin polymerization. (A) Cell cycle analysis of KG1a cells 
treated with glucopsychosine.  KG1a cells were treated with glucopsychosine at 1, 5, and 10 µM 
for 24 hrs. The cells were fixed and stained with PI according to literature protocol.  DNA content 
was assessed via flow cytometry using the Guava Soft Cell Cycle Analysis software. 0.2% DMSO 
was used as a negative control and nocodazole was used as a positive control.  Each peak represents 
the number of cells found with that amount of DNA (1X, 1X to 2X, or 2X). (B) Tubulin 
polymerization experiment.  Polymerization rates were assessed with the tubulin polymerization 
protocol and compared against a depolymerizer (nocodazole) and a promoter of polymerization 
(paclitaxel).  Purified tubulin was incubate with glucopsychosine at 50 and 100 µM and OD340 
nm readings were taken every 2.5 minutes until polymerization saturation occurred.    
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4.2.3 Calcium and the ER stress pathway 
Previous literature on glucopsychosine demonstrated that glucopsychosine increases 
intracellular calcium in rat brain microsomes [22]. Therefore, we looked at intracellular calcium 
increases with the fluo-3AM assay as explained in Ch. 3.2.5 and Ch. 3.3.4 in AML cell lines.  
We confirmed that glucopsychosine increased intracellular calcium levels within AML cell lines.  
Initially we hypothesized that glucopsychosine was increasing intracellular calcium levels and 
activating the ER stress response (refer to Ch. 1.3.2 Fig. 3).  We tested protein levels of GRP78, 
a chaperone protein which is released as a precursor to the UPR to prevent the cells from 
committing to the ER stress pathway of apoptosis [37, 95].  The ER is a center for protein folding 
and when there is insufficient protein folding, cytosolic GRP78 will shuttle unfolded proteins 
back into the ER to refold them [95].  We treated OCI-AML2 and U937 cells with 10 µM 
glucopsychosine for increasing time points and looked for changes in GRP78 protein expression 
(Fig. 11A). 
 The results of multiple Western blots showed no increase in GRP78 protein expression.  
However, to confirm that the ER stress pathway was not involved we probed for caspase-12 
activation.  Caspase-12 is normally bound to the ER as pro-caspase-12 until it becomes unbound 
and cleaved by calpains during ER stress [95].  Active caspase-12 can then initiate the caspase 
cascade and lead to apoptosis [38].  Our Western blots showed very slight increases in active 
caspase-12 (Fig. 11B) in OCI-AML2 cells but not U937.  
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Figure 11. Assessing the ER stress pathway of apoptosis. (A) GRP78 Western blot. OCI-AML2 
and U937 cells were treated with glucopsychosine at 10 µM for 0, 0.5, 8, and 24 hrs and whole 
cell lysates were Western blotted for GRP78 protein (78 kDa) according to standard Western blot 
protocol. (B) Caspase-12 Western blot showing uncleaved (50 kDa) and cleaved (40 kDa) caspase-
12. OCI-AML2 cells were incubated with 10 µM glucopsychosine at 0, 0.5, 8, and 24 hrs and 
changes in caspase-12 was observed.   
 
Because the activation of caspase-12 was modest and there was no increase in cytosolic 
GRP78, we excluded ER stress as the main pathway of glucopsychosine-mediated cell death.  At 
this point, we decided to test for caspase inhibitors, specifically Z-VAD and Q-VD-OPh (Fig. 5B 
and C).  The results from these experiments showed that in the presence of pan-caspase (Z-VAD) 
or caspase-3 specific (Q-VD-OPh) inhibitors, glucopsychosine was still cytotoxic to AML cells.  
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Since caspases were not essential to the mechanism of glucopsychosine, we assessed alternative 
proteases capable of initiating caspase-independent apoptosis.   
4.2.4 Calpains and calcium 
We purchased a commercially available calpain activation assay to assess calpain activity 
(refer to Ch. 3.2.7 and Fig. 6B, left panel). The results from these assays, summarized in Ch. 
3.3.4, demonstrate a significant (p < 0.005) increase in active calpain.  In addition, calpain 
protein expression was assessed by Western blotting (Fig. 6B, middle panel). Similar to the 
activation assay, there was an increase in active calpain, as determined by Western blot analysis.  
Moreover, when we inhibited calpain with MDL28170 we prevented calpain activation and 
abrogated cell death (Fig. 6B, right panel).  Finally, it has been shown that AML cells have 
upregulated levels of calpain [44].  To determine if calpain levels were a predictor of 
glucopsychosine’s ability to induce death, we tested calpain protein levels in multiple 
glucopsychosine sensitive cell lines and compared them to cells lines that were less sensitive to 
glucopsychosine treatment by Western blot analysis (Fig. 12). 
 
Figure 12.  Basal levels of calpain expression. (A) Dose-response curve of glucopsychosine in 
multiple cell lines. (B) Western blot of basal calpain expression across multiple cell lines.   
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There was no correlation between calpain expression and glucopsychosine sensitivity 
among the cell lines assayed.  While the LP1 (myeloma cell line), K562 (CML), and TEX (AML 
stem cell initiating line) were insensitive to glucopsychosine (Fig. 12A, left panel), only LP1 
followed our hypothesis that less sensitive cell lines would have reduced calpain expression.    
The last set of experiments aimed to identify the source of the intracellular calcium 
increases.  In addition to the calcium experiments discussed in Ch. 3.3.5., we used the calcium 
quantification assay in a primary AML patient sample and normal CD34+ sample that we had in 
excess (Figure 13).  After treating these samples with glucopsychosine at 0, 5, 10, and 20 µM for 
8 h, we have shown that in our normal CD34+ cells, cytosolic Ca2+ levels did not increase.  
Therefore glucopsychosine is not increasing calcium in normal hematopoietic cells.  However, 
when primary AML samples were exposed to glucopsychosine under the same conditions, there 
was an insignificant increase in calcium (ANOVA (F(3,4) = 5.355, p > 0.05, r = 0.6676) with 5 
µM glucopsychosine.  These results strengthen our hypothesis that increasing cytosolic calcium 
plays a key role in glucopsychosine’s mechanism of action and selectivity.  
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Figure 13.  Fluo 3-AM cytosolic Ca2+ quantification assay in normal CD34+ sample and 
primary AML patient sample. Cells were subjected to increasing concentrations of GLU (0, 5, 
10, 20 µM) for 8 h and cytosolic Ca2+ levels were quantified via flow cytometry and fluo-3AM/PI 
staining. (A) Normal CD34+ and (B) primary AML patient sample #3 cells.  
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CHAPTER 5:  DISCUSSION 
5.1 Summary of findings 
This project investigated the anti-cancer treatment properties of glucopsychosine, a 
nutraceutical derived from bovine milk.  We accomplished this by assessing glucopsychosine’s 
in vitro and in vivo effects in AML cells and mouse models.  In addition, we identified a unique 
characteristic of AML cells through interrogation of available mRNA databases of calcium 
surface channel expression, which showed that they were significantly down-regulated in AML 
cells compared to normal myeloid cells.  Coupling this information with the recent discovery that 
AML cells have basally increased calpain levels with an associated down-regulation of the 
calpain inhibitor, calpastatin, gives a plausible hypothesis for glucopsychosine’s preferential 
selectivity for AML cells (discussed below).   
5.2 Glucopsychosine’s mechanism of action 
From our study, we showed that glucopsychosine was cytotoxic to multiple AML cell 
lines, primary AML patient samples, and was able to reduce the size of tumors in NOD/SCID 
mice.  In contrast, glucopsychosine was not cytotoxic to non-AML cell lines (RWPE and CD44+ 
normal hematopoietic cells) and was not toxic in mice according to the physiological markers 
tested (i.e., weight loss, red blood cell counts, hemoglobin levels or serum markers of kidney and 
liver damage).  Through mechanistic studies, glucopsychosine increased cytosolic calcium levels 
leading to the cytotoxic activation of calpain proteases.  Extracellular calcium was functionally 
important for glucopsychosine-mediated cell death.  Cell viability assays in calcium-free media 
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or in combination with surface calcium inhibitors neutralized glucopsychosine’s cytotoxicity in 
AML cells (Fig. 7).  We hypothesize that glucopsychosine is able to modulate the ability of 
plasma membrane calcium channels to allow the influx of extracellular calcium.  
It is well established that cells tightly maintain the levels of intracellular calcium [46, 67].  
Because all cells require a controlled intracellular environment, the plasma membrane is integral 
in maintaining homeostasis.  The plasma membrane is a dynamic structure which can passively 
or actively allow the diffusion of solutes and ions through channels and pumps.  Extracellular 
pumps are a common target for therapies across multiple diseases [96, 97].  Lidocaine, a local 
anesthetic that blocks voltage-gated sodium channels (Nav1), is administered for the treatment of 
neuropathic pain [96].  Nicotine is an example of an agonist for the nicotinic acetylcholine 
receptor (nAChR) subtypes, mimicking the effects of acetylcholine binding [97].   
Although we did not identify the specific surface calcium channel that was modulated by 
glucopsychosine, we were able to prevent glucopsychosine induced cell death by concomitantly 
treating AML cells with verapamil, an L-type calcium channel inhibitor (Fig. 7A, left panel).  
However, calcium influx was not completely blocked by verapamil (Fig. 7A, right panel).  Thus, 
L-type calcium channels are not glucopsychosine’s only target and it is possible that 
glucopsychosine may be acting on multiple surface channels simultaneously. Future studies 
could focus on systematically knocking down each channel to identify which channel(s) are 
involved in glucopsychosine mediated cell death.  Regardless of the specific channel(s) being 
modulated, extracellular calcium was shown to be essential to glucopsychosine’s mechanism of 
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action because removing calcium from the media effectively blocked cell death and reduced 
increases in intracellular Ca2+ levels (Fig. 7B).  
The influx of calcium into the cells triggered a pathway of apoptosis mediated by 
calpains.  Glucopsychosine treatment increased calpain activation and protein levels.  This was 
functionally important as cell death was abrogated when co-incubated with MDL28170, a calpain 
inhibitor [98](Fig. 6B).  Our experimental results show that calpains are the main executioner 
proteases; however, we are not discrediting the parallel pathways that can also be at work 
simultaneously.  Once activated, caspases and calpain have many overlapping protein targets 
including pro-caspase-3 and -7, structural proteins (eg. actin), and DNA repair proteins (eg. 
PARP) [36, 99].  Calpains are less specific in their substrate candidates and have been reported to 
inactivate a number of caspases by proteolytic cleavage [100].  Caspases have also been 
implicated in the cleavage of calpastatin from calpains thereby activating them [99].   
The role of caspases in glucopsychosine cytotoxicity has never been reported prior to this 
study.  A related study by Sueyoshi et al. (2001) [101] investigated the caspase-independent cell 
death pathway of lysosphingolipids in neuronal cells.  They reported that Neuro2a cells exposed 
to lysosphingolipids increased caspase-3 activity and laddered DNA.  The DNA fragmentation 
was caspase-3-independent because total inhibition of caspase-3 with Z-VAD did not prevent 
DNA laddering.  Interestingly, they commented that glucopsychosine could be mechanistically 
similar, but this was not deliberated further or experimentally tested [101].  When we assessed 
caspase activation in glucopsychosine treated AML cells we saw insignificant increases in 
caspase 3/7 activation (Fig. 9B).  However, Q-VD-OPh (a caspase 3/7 inhibitor) did not affect 
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glucopsychosine cytotoxicity.  We also showed that the intrinsic mitochondrial pathway was not 
induced by glucopsychosine because Jurkat cells lacking functional mitochondrion were as 
susceptible as normal Jurkat cells to glucopsychosine (Fig. 5C, right panel).  Treatment with 
cyclosporin A (Ch. 3.8 Supp. Fig. 2), an mPTP inhibitor [102], did not prevent cell death and 
there was no increase in cytochrome c (an inner mitochondrial membrane protein) in response to 
glucopsychosine treatment (Fig. 9C).    
In our experiments, when Z-VAD (a pan-caspase inhibitor) was used at 100 µM in the 
presence of glucopsychosine, cells were slightly protected from cytotoxicity (Fig. 5B, right 
panel).  However, Z-VAD at concentrations of 100 µM or greater have been reported to cause 
unspecific inhibition of calpains and other proteases [42]. Although not formally tested, this 
provides a rationale for the observed protective effects of high Z-VAD concentrations.  
Alternatively, Z-VAD could be preventing caspases from inactivating calpastatin, thereby 
preventing calpain activation [103].  Therefore, since only MDL28170 (a calpain protease 
inhibitor) was able to abrogate cell death, we conclude that calpains and not caspases are 
functionally important for glucopsychosine-induced death.   
5.3 Selectivity of glucopsychosine 
An effective chemotherapeutic must show selectivity towards malignant cells.  Here we 
showed that glucopsychosine was selective towards cancerous cells and was most sensitive in 
leukemia cells.  Glucopsychosine did not reduce the cell viability of the CD34+ normal 
hematopoietic population of cells at concentrations up to 20 µM over 24 hours (with Annexin 
V/PI).  When we assessed glucopsychosine in primary AML patient samples, a trend appeared 
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that showed cell cytotoxicity plateauing at higher concentrations.  It is possible that 
glucopsychosine is saturating its target calcium channel(s) at higher concentrations and therefore 
increases in glucopsychosine will not lead to increases in calcium influx.  This hypothesis is 
strengthened by the fact that surface calcium channel expression is down-regulated in AML 
patients which suggests that saturation can occur more readily. 
In this study, in collaboration with Dr. Mahadeo Sukhai from the Princess Margaret 
Cancer Centre, we determined that the expression of surface calcium channels across AML 
patients from various AML subtypes (M0-M4) were significantly under-expressed compared to 
normal hematopoietic cells (CD34+, polymorphonuclear leukocytes, and promyelocytes) 
(Supplementary Tables 2 and 3).  There is still debate whether down-regulation of calcium 
channels confers a pro-survival or pro-death phenotype during the differentiation of cancer cells.  
Yang et al. (2013) [104] performed a similar expression database screen looking at levels of 
calcium-activated chloride channels (CLCAs) in colorectal cancer (CRC) patients and normal 
colonic mucosa.  They found that in CRC patients, CLCAs were significantly under expressed 
which was functionally important for blocked differentiation and increased proliferation [104].   
We believe that AML cells are under-expressing their surface calcium channels for similar 
reasons - to evade calcium triggered cell death and growth arrest.  
It is common for cells to have altered physiological morphology in diseased states as seen 
in atrial fibrillation [72], colonic inflammation [73] and cerebral ischemia [74].  In the same way, 
cancerous cells take on an altered physiological morphology.  For example, PMCA2 
(Plasmalemmal Ca2+ ATPases 2) is over-expressed in breast cancer and plays a role in conferring 
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resistance to apoptotic signals [67, 105].  Baggott et al. (2012) [105] showed that targeting and 
disrupting the function of PMCA2 promoted apoptosis and paclitaxel-induced death in breast 
cancer cells.  Therefore, we believe that glucopsychosine counters the pro-survival mechanism 
conferred by the under expressed surface calcium channels in AML cells.   
The second factor that may contribute to glucopsychosine’s selectivity relates to calpain 
and calpastatin levels in AML cells compared to normal cells.  Calpain activity has been reported 
in numerous pathological states to be increased.  Niapour et al. (2012) [44] showed that calpain 
activity is highly elevated in the CD34+/CD38- populations of AML subtypes.  The elevated 
levels of calpains conferred a pro-survival mechanism because treatment with PD150606 (a 
calpain inhibitor) induced apoptosis [44]. Their study also showed that calpain levels were 
significantly lower in CD34+ cells of complete remission patients compared to those patients 
who had no response to treatment. Therefore, calpain can be used as a potential prognostic factor 
for determining treatment options in AML therapy.  In combination with this finding, calpastatin 
levels were inversely related to calpain levels in AML cells [44].  This relationship amplifies the 
potential effectiveness of activating calpains in AML (Fig. 14).  Thus we propose that AML cells 
down-regulate their plasma calcium channels to prevent increases in cytosolic calcium from non-
specifically activating calpains past a point where they initiate cell death.  Glucopsychosine 
exploits this and selectively increases calcium in AML cells.  This implies that increased calpains 
render AML cells more sensitive to glucopsychosine.  Although, we were unsuccessful in our 
crude attempt (i.e., Western blotting) to correlate calpain levels and cell line glucopsychosine 
sensitivity, future studies would be needed to use more precise measures of calpain content. 
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Figure 14. Simplified schematic noting the cellular differences between normal 
hematopoietic cells and AML cells.  Normal cells have normal levels of surface calcium channels 
and calpastatin which prevent calpains from being activated by normal calcium flux.  AML cells 
have reduced surface calcium channels and increased unbound calpain which confer pro-survival 
mechanisms.   
   
5.4 Glucopsychosine as a novel therapy for AML 
A major goal of this research was to perform pre-clinical studies to assess 
glucopsychosine for its potential as a novel anti-AML agent.  Currently glucopsychosine is not 
being marketed as a nutraceutical or a chemotherapeutic, but this research shows that 
glucopsychosine can have therapeutic effects.  Furthermore, the characterization of the different 
cell and molecular properties of AML cells, with regard to their calcium channel expression, are 
alone an important contribution to the field.  In this section we discuss the implications of 
glucopsychosine for the treatment of AML. 
The first consideration is the mode of glucopsychosine administration.  Glucopsychosine 
is a sphingolipid that can be synthesized chemically.  It is naturally found at low concentrations 
in milk (0.067 g/L or 0.15 µM) [81], thus in order to reach therapeutic levels, glucopsychosine 
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must be concentrated and administered as a nutraceutical.  According to Lipinski’s rule of five 
[106], glucopsychosine would not be suitable as an oral formulation due to its 6 H-bond donors, 
large polar surface area (145.63 Å2), and 18 rotatable bonds1 and would therefore be 
administered via intravenous route.  There is limited literature on pharmacokinetic properties of 
glucopsychosine in humans or murine models.  However, studies have shown that 
glucopsychosine levels are greatly elevated in the brain of type 2 and 3 Gauchers disease patients 
[83].  In type 1 Gauchers disease, which is the form of the lysosomal storage disorder that does 
not include the central nervous system, plasma levels of glucopsychosine was on average more 
than 200-fold greater than in healthy subjects.  Although glucopsychosine was present at such 
high concentrations in the plasma of Gauchers disease patients, there was no significant 
correlation to disease pathology [83].  Therefore, while glucopsychosine treatment may increase 
plasma concentrations in humans, there is no documented correlation with disease pathology.  
Furthermore, our in vivo study showed that glucopsychosine administered at twice the 
concentration needed to reduce tumour growth (i.e., 40mg/kg) had no signs of toxicity in mice.  
Nonetheless, future studies would be needed to determine acceptable therapeutic doses for 
rotating glucopsychosine into standard regimens.   
Calcium channels are key targets in cardiac pharmacology and calcium channel blockers 
are usually employed to prevent tachycardias [107].  Because the sinoatrial and atrio-ventricular 
nodes are very concentrated in calcium channels, calcium increases are very prevalent in these 
regions and causes the increased conduction through the AV node.   In addition, calcium 
                                                 
1 Values were calculated with JChem computational software. 
  70 
channels are present in smooth muscles lining blood vessels [108].  Patients with a history of 
hypertension have increased intracellular calcium levels and may be on hypertension medication 
such as the calcium channel blockers nifedipine, amlodipine, diltiazem, or verapamil [109]. 
Therefore, simultaneous use of these calcium channel blockers could interfere with 
glucopsychosine’s mechanism of action in AML cells, as seen in vitro with verapamil (Fig. 7A). 
Future human studies would need special consideration for patients with a history of heart 
disease and/or on prescription medication for blocking of calcium channels.  
5.5 Limitations 
As mentioned in Chapter 5.3, the initial screen used RWPE a prostate cell line which may 
have different growth kinetics and features compared to AML cells or normal hematopoietic 
cells.  Alternatively, non-cancerous lymphocytes, monocytes, granulocytes, or bone marrow cells 
would have been better suited to assess the selectivity of the validated compounds.  However, 
RWPE cells did serve as a “normal” epithelial cell line, and the use of “normal lines” is common 
in literature [59, 76].  In addition, the use of primary CD34+ normal hematopoietic cells rectified 
this limitation.  Another possible limitation of this screen was the number of cell lines used to 
test and validate.  The US National Cancer Institute use a special drug screen when looking for 
anticancer drugs which involves the use of 60 different cell lines from 9 different tumor types 
[110].  Our lab does not have access to this number of cell lines and initially the NCI employed 
these precondition in hopes to limit the use of xenograft mouse models unnecessarily [110].  
Therefore, we did not feel the need to expand our validation screen to a larger number of cell 
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lines since we were able to show glucopsychosine’s therapeutic effect in xenograft mouse 
models. 
The second limitation to this study would be the use of a tumor xenograft model.  The 
xenograft model is an established model that has been used countlessly in AML and cancer 
research [111, 112].  However, there are advantages and disadvantages when using xenograft 
tumors.  The main disadvantage with xenograft tumor models for AML is that it does not reflect 
the pathophysiology of AML.  AML is a cancer of the blood and does not naturally form a solid 
tumor mass.   However, when assessed in xenograft mouse models, the AML cells are able to 
congregate into a mass.  The advantage of this model is the ability to visualize and measure 
tumor response to glucopsychosine treatment [113].  In addition, this is the standard model by 
which pre-clinical assessment is performed, and although limited in predicting clinical success, it 
is a very useful tool for physiological assessment [113]. The safety and toxicity data collected 
from this experiment is not diminished by the limitations of the xenograft model.  
The last experiment which posed limitations to this study was the calcium-free media 
experiment looking at the importance of extracellular calcium to glucopsychosine-mediate cell 
death.  Due to the importance of extracellular calcium for normal cellular function, suspending 
AML cells in calcium free media caused toxicity at 24 hours.  In order to adjust for this we used 
glucopsychosine at higher concentrations (20 µM) and shorter time points (0, 30, 60 minutes).  
Therefore it is uncertain whether or not the cells were behaving the same as they would normally 
behave in regular media.  We also noticed that when performing the Annexin PI cell viability 
assay we saw that in calcium free media the cells did not have an ANN+/PI- fraction which 
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designates early apoptosis.  However, this is likely due to phophatidylserine’s dependence on 
calcium to flip to the outer leaflet of the plasma membrane to be bound by annexin [114].  
Therefore, although we saw that cell death was inhibited, we were not able to assess whether 
early apoptosis was also being inhibited by the calcium-free media.  
5.6 Conclusion 
The conclusions made from this thesis have opened up many more avenues of potential 
study.  Glucopsychosine has a mechanism of action that is unique to current AML therapy – 
calpain-mediated cell death.  Future studies will need to clarify the exact pathway of 
glucopsychosine induced cell death (which calcium channels are being targeted and what cellular 
substrate is calpain targeting) and investigate its pharmacokinetic properties in mouse and human 
models.  Cancer therapy is constantly changing with new therapies and dosing regimens 
continuously fine-tuning the current state of treatment.  This study was aimed at accomplishing 
this in acute myeloid leukemia, a disease that is far from cured.  The results, insights, and 
experimental reasoning used in this project can all be used to realize this goal. 
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Appendix 1 
Supplementary Table 2. List of under-expressed calcium channels in AML. Interrogation of publically available data sets revealed a list 
of 33 genes that are significantly under-expressed (>1.25 fold; p<0.001) in AML cells compared to normal cells.  
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Appendix 2 
Supplementary Table 3. List of over-expressed calcium channels in AML. Interrogation of publically available data sets revealed a list 
of 17 genes that are significantly over-expressed (>1.25 fold; p<0.001) in AML cells compared to normal cells. 
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p-value 0.8822 0.3046 0.0023 0.8783 0.392 0.143 0.0677 0.3608 0.1835 0.5361 0.1311 0.0239 0.0575 0.9063 0.0545 0.012
Ratio 0.9898 0.828 1.8258 0.9693 1.0743 1.9293 1.7286 1.1704 0.7792 1.2596 1.2388 1.3868 1.6742 0.9862 1.1326 1.163
Fold-Change -1.0103 -1.2077 1.8258 -1.0317 1.0743 1.9293 1.7286 1.1704 -1.2833 1.2596 1.2388 1.3868 1.6742 -1.0139 1.1326 1.163
Description down down up down up up up up down up up up up down up up
p-value 0.0002 7E-14 0.6006 3E-05 0.0094 0.8757 0.0206 1E-05 0.0098 4E-07 0.0053 4E-06 0.5703 6E-05 0.1905 9E-08
Ratio 1.3264 5.4729 1.11 2.5476 1.2581 1.075 2.0617 2.2635 1.6647 8.3628 1.5168 2.0778 0.8538 1.6743 1.0913 1.4286
Fold-Change 1.3264 5.4729 1.11 2.5476 1.2581 1.075 2.0617 2.2635 1.6647 8.3628 1.5168 2.0778 -1.1712 1.6743 1.0913 1.4286
Description up up up up up up up up up up up up down up up up
p-value 0.166 0.7891 0.0128 0.0797 0.1446 0.0002 7E-05 0.6654 0.6972 0.7368 0.5198 0.0528 0.0395 0.4129 0.0721 0.0231
Ratio 0.9077 0.9519 1.6326 0.696 1.1314 5.7389 3.4757 1.0776 1.0758 0.8816 1.0956 1.3242 1.7561 0.9075 1.1241 1.1467
Fold-Change -1.1017 -1.0506 1.6326 -1.4368 1.1314 5.7389 3.4757 1.0776 1.0758 -1.1343 1.0956 1.3242 1.7561 -1.1019 1.1241 1.1467
Description down down up down up up up up up down up up up down up up
p-value 0.0184 1E-17 0.0926 7E-06 0.1122 0.6291 0.2295 0.5093 5E-05 0.8345 0.8971 2E-07 0.021 0.0004 0.4692 0.1586
Ratio 0.8118 0.0814 1.507 0.2944 1.1833 0.7625 0.6374 1.1536 0.3668 1.103 0.9773 0.3649 2.2086 0.5811 1.0602 1.111
Fold-Change -1.2318 -12.292 1.507 -3.3967 1.1833 -1.3114 -1.5688 1.1536 -2.7262 1.103 -1.0232 -2.7404 2.2086 -1.7208 1.0602 1.111
Description down down up down up down down up down up down down up down up upP
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Appendix 3 
Supplementary Table 4. Calcium channel gene information. 
 
Gene 
Symbol Gene Title RefSeq Transcript ID
ATP2A3 ATPase, Ca++ transporting, ubiquitous
NM_005173 /// NM_174953 /// NM_174954 /// 
NM_174955 /// NM_174956 /// NM_174957 
ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 NM_001001331 /// NM_001683
ATP2C2 ATPase, Ca++ transporting, type 2C, member 2 NM_014861
CACNA1C
calcium channel, voltage-dependent, L type, alpha 
1C subunit
NM_000719 /// NM_001129827 /// NM_001129829 
/// NM_001129830 /// NM_001129831 //
CACNA1D
calcium channel, voltage-dependent, L type, alpha 
1D subunit NM_000720 /// NM_001128839 /// NM_001128840
CACNA1E
Calcium channel, voltage-dependent, R type, 
alpha 1E subunit NM_000721
CACNA1G
calcium channel, voltage-dependent, T type, alpha 
1G subunit
NM_018896 /// NM_198376 /// NM_198377 /// 
NM_198378 /// NM_198379 /// NM_198380 
CACNA2D
1
calcium channel, voltage-dependent, alpha 2/delta 
subunit 1 NM_000722
CACNB1
calcium channel, voltage-dependent, beta 1 
subunit NM_000723 /// NM_199247 /// NM_199248
CACNB2
calcium channel, voltage-dependent, beta 2 
subunit
NM_000724 /// NM_001167945 /// NM_201570 /// 
NM_201571 /// NM_201572 /// NM_2015
CACNG1
calcium channel, voltage-dependent, gamma 
subunit 1 NM_000727
CACNG4
calcium channel, voltage-dependent, gamma 
subunit 4 NM_014405
CACNG5
calcium channel, voltage-dependent, gamma 
subunit 5 NM_014404 /// NM_145811
KCNMA1
potassium large conductance calcium-activated 
channel, subfamily M, alpha member
NM_001014797 /// NM_001161352 /// 
NM_001161353 /// NM_002247
KCNMB2
potassium large conductance calcium-activated 
channel, subfamily M, beta member NM_005832 /// NM_181361
ORAI2
ORAI calci m release-activated calcium modulator 
2 NM_001126340 /// NM_032831
SLC24A4
solute carrier family 24 
(sodium/potassium/calcium exchanger), member 
4 NM_153646 /// NM_153647 /// NM_153648
SLC24A5 solute carrier family 24, member 5 NM_205850
SLC8A1
solute carrier family 8 (sodium/calcium 
exchanger), member 1
NM_001112800 /// NM_001112801 /// 
NM_001112802 /// NM_021097
TACSTD2 tumor-associated calcium signal transducer 2 NM_002353
TRPA1
transient receptor potential cation channel, 
subfamily A, member 1 NM_007332
TRPC1
transient receptor potential cation channel, 
subfamily C, member 1 NM_003304
TRPC4
transient receptor potential cation channel, 
subfamily C, member 4
NM_001135955 /// NM_001135956 /// 
NM_001135957 /// NM_001135958 /// NM_003306 //
TRPC4AP
transient receptor potential cation channel, 
subfamily C, member 4 associated pr NM_015638 /// NM_199368
TRPC6
transient receptor potential cation channel, 
subfamily C, member 6 NM_004621
TRPM1
transient receptor potential cation channel, 
subfamily M, member 1 NM_002420
TRPM2
transient receptor potential cation channel, 
subfamily M, member 2 NM_003307
TRPM3
transient receptor potential cation channel, 
subfamily M, member 3
NM_001007470 /// NM_001007471 /// NM_020952 
/// NM_024971 /// NM_206944 /// NM_2
TRPM6
transient receptor potential cation channel, 
subfamily M, member 6 NM_001177310 /// NM_001177311 /// NM_017662
TRPM8
transient receptor potential cation channel, 
subfamily M, member 8 NM_024080
TRPV5
transient receptor potential cation channel, 
subfamily V, member 5 NM_019841
TRPV6
transient receptor potential cation channel, 
subfamily V, member 6 NM_018646
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Gene 
Symbol Gene Title RefSeq Transcript ID
ATP2A1
ATPase, Ca++ transporting, cardiac muscle, fast 
twitch 1 NM_004320 /// NM_173201
ATP2A2
ATPase, Ca++ transporting, cardiac muscle, slow 
twitch 2 NM_001135765 /// NM_001681 /// NM_170665
ATP2B4 ATPase, Ca++ transporting, plasma membrane 4 NM_001001396 /// NM_001684
ATP2C1 ATPase, Ca++ transporting, type 2C, member 1
NM_001001485 /// NM_001001486 /// 
NM_001001487 /// NM_014382
CACNA1I
calcium channel, voltage-dependent, T type, alpha 
1I subunit NM_001003406 /// NM_021096
CACNA2D
3
calcium channel, voltage-dependent, alpha 2/delta 
subunit 3 NM_018398
CACNA2D
4
calcium channel, voltage-dependent, alpha 2/delta 
subunit 4 NM_172364
ORAI1
ORAI calcium release-activated calcium modulator 
1 NM_032790
PANX1 pannexin 1 NM_015368
SLC24A3
solut  carrier family 24 
(sodium/potassium/calcium exchanger), member 
3 NM_020689
SLC8A3
solute carrier family 8 (sodium/calcium 
exchanger), member 3
NM_001130417 /// NM_033262 /// NM_058240 /// 
NM_182932 /// NM_182936 /// NM_1830
TRPM7
transient receptor potential cation channel, 
subfamily M, member 7 NM_017672
TRPS1 trichorhinophalangeal syndrome I NM_014112
TRPT1 tRNA phosphotransferase 1
NM_001033678 /// NM_001160389 /// 
NM_001160390 /// NM_001160392 /// 
NM_001160393
TRPV3
transient receptor potential cation channel, 
subfamily V, member 3 NM_145068
TRPV4
transient receptor potential cation channel, 
subfamily V, member 4
NM_001177428 /// NM_001177431 /// 
NM_001177433 /// NM_021625 /// NM_147204
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Appendix 4 
 
MDL28170 inhibits increases in apoptosis.  Glucopsychosine was co-incubated with MDL28170 
for increasing duration and apoptosis was measured by the ANN/PI assay.  
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Appendix 5 
 
 
Eight NOD/SCID mice were injected with human leukemia cell lines and monitored for the 
presence of tumors and toxicity.  Mice 1-4 comprised Group 1 and mice 5-8 comprised Group 2.  
(A) Tumor volumes were recorded three times weekly.  Endpoint was determined when tumor 
volumes exceeded 1000 mm3.  (B) Body weights of each mouse shows no sign of toxicity due to 
experiment. Subcutaneous cell line injections were performed by Julia Guan.  Mouse weights and 
tumor measurements were done by Leonard Angka and Eric Lee.  Cardiac puncture was performed 
by Leonard Angka and Julia Guan.   
 
